BRIGHTFOCUS FOUNDATION: Form 990, tax year 2024

View the entire original 990 at ProPublica ↗

Organization: BRIGHTFOCUS FOUNDATION (EIN 23-7337229)
Tax period: 2024-04-01 to 2025-03-31
Filed: 2025-10-23
IRS object ID: 202522969349300607
Schema version: 2024v5.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2025-10-23T07:39:01-05:00	ReturnTs
Tax Period End	2025-03-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	881478669	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	CBIZ ADVISORS LLC	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	1899 L STREET NW 850	AddressLine1Txt
City	WASHINGTON	CityNm
State Abbreviation	DC	StateAbbreviationCd
ZIP	20036	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2024-04-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	237337229	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	BRIGHTFOCUS FOUNDATION	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	BRIG	BusinessNameControlTxt
Phone	3019483244	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	22512 GATEWAY CENTER DRIVE	AddressLine1Txt
City	CLARKSBURG	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20871	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	STACY PAGOS HALLER	PersonNm
Person Title	PRESIDENT/CEO	PersonTitleTxt
Phone	3019483244	PhoneNum
Signature	2025-10-22	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (1)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	FRANK SMITH	PreparerPersonNm
PTIN	P00639053	PTIN
Phone	2022274000	PhoneNum
Preparation	2025-10-22	PreparationDt

Field	Value	IRS element (for citing)
Tax	2024	TaxYr
Build TS	2025-03-06 01:10:19Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	STACY PAGOS HALLER	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	22512 GATEWAY CENTER DRIVE	AddressLine1Txt
City	CLARKSBURG	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20871	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$89,178,037	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.BRIGHTFOCUS.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1973	FormationYr
Legal Domicile State	DC	LegalDomicileStateCd
Activity Or Mission	BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.	ActivityOrMissionDesc
Voting Members Governing Body	14	VotingMembersGoverningBodyCnt
Voting Members Independent	14	VotingMembersIndependentCnt
Total Employee	59	TotalEmployeeCnt
Total Volunteers	85	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$43,373,203	PYContributionsGrantsAmt
CY Contributions Grants	$52,879,488	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$4,702,264	PYInvestmentIncomeAmt
CY Investment Income	$9,840,578	CYInvestmentIncomeAmt
PY Other Revenue	$587,403	PYOtherRevenueAmt
CY Other Revenue	$703,858	CYOtherRevenueAmt
PY Total Revenue	$48,662,870	PYTotalRevenueAmt
CY Total Revenue	$63,423,924	CYTotalRevenueAmt
PY Grants And Similar Paid	$10,704,093	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$16,943,701	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$6,876,671	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$6,479,211	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$952,781	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$1,027,076	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$13,859,870	CYTotalFundraisingExpenseAmt
PY Other Expenses	$27,683,861	PYOtherExpensesAmt
CY Other Expenses	$28,845,021	CYOtherExpensesAmt
PY Total Expenses	$46,217,406	PYTotalExpensesAmt
CY Total Expenses	$53,295,009	CYTotalExpensesAmt
PY Revenues Less Expenses	$2,445,464	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$10,128,915	CYRevenuesLessExpensesAmt
Total Assets BOY	$63,464,652	TotalAssetsBOYAmt
Total Assets EOY	$65,129,292	TotalAssetsEOYAmt
Total Liabilities BOY	$37,245,915	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$28,168,825	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$26,218,737	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$36,960,467	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$21,402,299	ExpenseAmt
Grant	$10,412,240	GrantAmt
Desc	ALZHEIMER'S DISEASE RESEARCH (ADR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$10,955,751	ExpenseAmt
Grant	$5,329,984	GrantAmt
Desc	MACULAR DEGENERATION RESEARCH (MDR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$2,469,629	ExpenseAmt
Grant	$1,201,477	GrantAmt
Desc	NATIONAL GLAUCOMA RESEARCH (NGR) PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$34,827,679	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (1)	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	0	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (1)	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (1)	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	Yes (1)	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	88	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	59	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (1)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (1)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	14	GoverningBodyVotingMembersCnt
Independent Voting Member	14	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Other Website	Yes (X)	OtherWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	JONATHAN WALSH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	3015569385	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	22512 GATEWAY CENTER DRIVE	AddressLine1Txt
City	CLARKSBURG	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20871	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (24 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
PATRICIA M STEWART
CHAIR	10.00	Yes (X)	Yes (X)	$0	$0	$0
SCOTT KAISER MD
SECRETARY UNTIL 06/24, VICE CHAIR	6.00	Yes (X)	Yes (X)	$0	$0	$0
THOMAS F FREDDO OD PHD
DIRECTOR UNTIL 06/24, SECRETARY	6.00	Yes (X)	Yes (X)	$0	$0	$0
SHAWNA GOTTLIEB
TREASURER	6.00	Yes (X)	Yes (X)	$0	$0	$0
CECILIA ARRADAZA
VICE CHAIR UNTIL 06/24, DIRECTOR	6.00	Yes (X)	Yes (X)	$0	$0	$0
PAUL CAMPBELL
DIRECTOR	5.00	Yes (X)		$0	$0	$0
HERBERT L DRAYTON III
DIRECTOR	5.00	Yes (X)		$0	$0	$0
DANA GRIFFIN
DIRECTOR	5.00	Yes (X)		$0	$0	$0
TONYA MATTHEWS PHD
DIRECTOR	5.00	Yes (X)		$0	$0	$0
ANN SECLOW
DIRECTOR	5.00	Yes (X)		$0	$0	$0
JAN M STOUFFER PHD
DIRECTOR	6.00	Yes (X)		$0	$0	$0
ADAM MYERS
DIRECTOR AS OF 04/24	5.00	Yes (X)		$0	$0	$0
JOHN PENN
DIRECTOR AS OF 03/25	5.00	Yes (X)		$0	$0	$0
DALE YOUNG
DIRECTOR AS OF 03/25	5.00	Yes (X)		$0	$0	$0
STACY PAGOS HALLER
PRESIDENT/CEO	45.00		Yes (X)	$424,828	$0	$46,677
NANCY KEACH
SR. VP, STRATEGIC PARTNERSHIPS	45.00			$270,157	$0	$51,713	Yes (X)
R BRIAN ELDERTON
SR. VP, DEVELOPMENT	45.00			$261,323	$0	$40,046	Yes (X)
JONATHAN WALSH
SVP, FINANCE & ADMINISTRATION	45.00			$226,786	$0	$4,251	Yes (X)
DIANE BOVENKAMP PHD
VP, SCIENTIFIC AFFAIRS	45.00			$196,242	$0	$24,358	Yes (X)
KACI BAEZ - VP INTEGRATED
MKTING & COMM. UNTIL 06/24	45.00			$110,647	$0	$8,838		Yes (X)
PREETI SUBRAMANIAN - PHD DIR
OF SCIENT. PROGRAMS, VISION SCIENCE	40.00			$139,931	$0	$16,400		Yes (X)
LISA MORGAN
SENIOR DIRECTOR, ANNUAL GIVING	40.00			$135,115	$0	$22,867		Yes (X)
SHARYN ROSSI - PHD DIR OF
SCIENT. PROGRAMS, NEUROSCIENCE	40.00			$125,732	$0	$42,143		Yes (X)
JEFFREY HONAKER
SR. MGR. OPS AND BUILDING	40.00			$115,469	$0	$33,854		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$2,006,230	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$291,147	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	12	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
RKD GROUP
35 PARKWOOD DRIVE SUITE 160	HOPKINTON	MA	01748	PUBLIC AWARENESS CONSULTING & MATERIALS	$12,374,028
ADSTRA LLC
750 COLLEGE ROAD EAST STE 201	PRINCETON	NJ	08540	MAIL LIST RENTAL	$1,758,266
DATA MANAGEMENT INC
160 STONE STREET	STONEVILLE	NC	27048	DATABASE MANAGEMENT	$310,839
ROYAL SONESTA CHICAGO DOWNTOWN
71 E WACKER DRIVE	CHICAGO	IL	60601	HOTEL CONFERENCE	$219,320
THE ROBERT JOSEPH GROUP
6901 ROCKLEDGE DRIVE	BETHESDA	MD	20817	FINANCE AND ACCOUNTING	$213,430

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	12	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$124,297	FederatedCampaignsAmt
Fundraising	$222,435	FundraisingAmt
All Other Contributions	$52,532,756	AllOtherContributionsAmt
Noncash Contributions	$394,954	NoncashContributionsAmt
Total Contributions	$52,879,488	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,052,357	TotalRevenueColumnAmt
Exclusion	$1,052,357	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$370,381	TotalRevenueColumnAmt
Exclusion	$370,381	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$565,015	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$179,056	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$385,959	RealAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$385,959	TotalRevenueColumnAmt
Exclusion	$385,959	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$22,404,949	SecuritiesAmt
Other	$11,871,081	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$21,893,998	SecuritiesAmt
Other	$3,593,811	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$510,951	SecuritiesAmt
Other	$8,277,270	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$8,788,221	TotalRevenueColumnAmt
Exclusion	$8,788,221	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$30,640	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$222,435	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$87,248	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$56,608	TotalRevenueColumnAmt
Exclusion	-$56,608	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

Field	Value	IRS element (for citing)
Desc	OTHER INCOME	Desc
Business	900099	BusinessCd
Total Revenue Column	$4,126	TotalRevenueColumnAmt
Exclusion	$4,126	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$4,126	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$63,423,924	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$10,544,436	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$13,267,808	TotalAmt
Program Services	$13,267,808	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$3,675,893	TotalAmt
Program Services	$3,675,893	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$1,652,825	TotalAmt
Program Services	$975,321	ProgramServicesAmt
Management And General	$365,576	ManagementAndGeneralAmt
Fundraising	$311,928	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$3,413,792	TotalAmt
Program Services	$1,685,554	ProgramServicesAmt
Management And General	$1,263,641	ManagementAndGeneralAmt
Fundraising	$464,597	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$327,893	TotalAmt
Program Services	$172,202	ProgramServicesAmt
Management And General	$105,437	ManagementAndGeneralAmt
Fundraising	$50,254	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$735,356	TotalAmt
Program Services	$386,193	ProgramServicesAmt
Management And General	$236,460	ManagementAndGeneralAmt
Fundraising	$112,703	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$349,345	TotalAmt
Program Services	$183,468	ProgramServicesAmt
Management And General	$112,335	ManagementAndGeneralAmt
Fundraising	$53,542	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$71,456	TotalAmt
Program Services	$38,524	ProgramServicesAmt
Management And General	$25,216	ManagementAndGeneralAmt
Fundraising	$7,716	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$118,544	TotalAmt
Program Services	$63,911	ProgramServicesAmt
Management And General	$41,833	ManagementAndGeneralAmt
Fundraising	$12,800	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$1,027,076	TotalAmt
Fundraising	$1,027,076	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$241,293	TotalAmt
Management And General	$241,293	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$1,441,677	TotalAmt
Program Services	$1,266,242	ProgramServicesAmt
Management And General	$147,747	ManagementAndGeneralAmt
Fundraising	$27,688	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$2,434,520	TotalAmt
Program Services	$1,230,126	ProgramServicesAmt
Fundraising	$1,204,394	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,270,619	TotalAmt
Program Services	$658,427	ProgramServicesAmt
Management And General	$135,325	ManagementAndGeneralAmt
Fundraising	$476,867	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$602,095	TotalAmt
Program Services	$326,769	ProgramServicesAmt
Management And General	$171,648	ManagementAndGeneralAmt
Fundraising	$103,678	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$368,766	TotalAmt
Program Services	$214,621	ProgramServicesAmt
Management And General	$114,177	ManagementAndGeneralAmt
Fundraising	$39,968	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$258,884	TotalAmt
Program Services	$221,715	ProgramServicesAmt
Management And General	$19,208	ManagementAndGeneralAmt
Fundraising	$17,961	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$876,230	TotalAmt
Program Services	$820,584	ProgramServicesAmt
Management And General	$24,020	ManagementAndGeneralAmt
Fundraising	$31,626	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$383,185	TotalAmt
Management And General	$383,185	ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$596,953	TotalAmt
Program Services	$332,227	ProgramServicesAmt
Management And General	$181,264	ManagementAndGeneralAmt
Fundraising	$83,462	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$54,674	TotalAmt
Program Services	$25,895	ProgramServicesAmt
Management And General	$14,298	ManagementAndGeneralAmt
Fundraising	$14,481	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PUB. AWARENESS POSTAGE	$9,119,632	$4,191,654	$528,303	$4,399,675
PUB. AWARENESS PRINTING	$6,362,574	$2,938,902	$276,015	$3,147,657
PUB. AWARENESS COMP.	$2,744,419	$1,277,945	$127,580	$1,338,894
LIST RENTAL	$1,899,500	$873,698	$92,899	$932,903

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$53,295,009	TotalAmt
Program Services	$34,827,679	ProgramServicesAmt
Management And General	$4,607,460	ManagementAndGeneralAmt
Fundraising	$13,859,870	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$19,360,619	TotalAmt
Program Services	$8,338,957	ProgramServicesAmt
Management And General	$982,887	ManagementAndGeneralAmt
Fundraising	$10,038,775	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$829,628	BOYAmt
EOY	$3,278,680	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$8,516,562	BOYAmt
EOY	$6,619,066	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$6,199,054	BOYAmt
EOY	$9,183,959	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$23,832	BOYAmt
EOY	$25,908	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$28,325	BOYAmt
EOY	$36,763	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$998,282	BOYAmt
EOY	$1,557,144	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$9,283,683	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$5,312,032	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$7,847,284	BOYAmt
EOY	$3,971,651	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$31,237,150	BOYAmt
EOY	$32,437,847	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$7,784,535	BOYAmt
EOY	$8,018,274	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$63,464,652	BOYAmt
EOY	$65,129,292	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$2,580,327	BOYAmt
EOY	$1,551,998	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$24,991,458	BOYAmt
EOY	$25,940,333	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$9,000,000	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$674,130	BOYAmt
EOY	$676,494	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$37,245,915	BOYAmt
EOY	$28,168,825	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$12,270,789	BOYAmt
EOY	$25,140,265	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$13,947,948	BOYAmt
EOY	$11,820,202	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$26,218,737	BOYAmt
EOY	$36,960,467	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$63,464,652	BOYAmt
EOY	$65,129,292	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	$10,128,915	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$502,498	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$110,317	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	0	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$48,502,473	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$46,522,410	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$43,451,535	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$43,373,203	CurrentTaxYearMinus1YearAmt
Current Tax Year	$52,879,488	CurrentTaxYearAmt
Total	$234,729,109	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$48,502,473	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$46,522,410	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$43,451,535	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$43,373,203	CurrentTaxYearMinus1YearAmt
Current Tax Year	$52,879,488	CurrentTaxYearAmt
Total	$234,729,109	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$91,938	SubstantialContributorsTotAmt
Public Support Total170	$234,637,171	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,887,633	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,074,361	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,972,869	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,910,285	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,987,753	CurrentTaxYearAmt
Total	$9,832,901	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus3 Years	$7,500	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus1 Year	$70	CurrentTaxYearMinus1YearAmt
Current Tax Year	$4,126	CurrentTaxYearAmt
Total	$11,696	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$244,573,706	TotalSupportAmt
Public Support CY170	0.95940	PublicSupportCY170Pct
Public Support PY170	0.95400	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	FormAndLineReferenceDesc
Explanation	SAVINGS BOND PAYOUT - 2021 AMOUNT: $ 7,500. MISCELLANEOUS - 2023 AMOUNT: $ 70. 2024 AMOUNT: $ 4,126.	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$52,292,944	FilingOrganizationsTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$52,292,944	FilingOrganizationsTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$286,823	BeginningYearBalanceAmt
Contributions	$8,079	ContributionsAmt
Investment Earnings Or Losses	-$8,079	InvestmentEarningsOrLossesAmt
Other Expenditures	$8,079	OtherExpendituresAmt
End Year Balance	$278,744	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$310,022	BeginningYearBalanceAmt
Contributions	$23,199	ContributionsAmt
Investment Earnings Or Losses	-$23,199	InvestmentEarningsOrLossesAmt
Other Expenditures	$23,199	OtherExpendituresAmt
End Year Balance	$286,823	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$325,000	BeginningYearBalanceAmt
Contributions	$14,978	ContributionsAmt
Investment Earnings Or Losses	-$14,978	InvestmentEarningsOrLossesAmt
Other Expenditures	$14,978	OtherExpendituresAmt
End Year Balance	$310,022	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$302,000	BeginningYearBalanceAmt
Contributions	$13,634	ContributionsAmt
Investment Earnings Or Losses	$23,000	InvestmentEarningsOrLossesAmt
Other Expenditures	$13,634	OtherExpendituresAmt
End Year Balance	$325,000	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$302,000	BeginningYearBalanceAmt
Contributions	$14,744	ContributionsAmt
Other Expenditures	$14,744	OtherExpendituresAmt
End Year Balance	$302,000	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.00000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	1.00000	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.00000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	Yes (1)	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,147,363	OtherCostOrOtherBasisAmt
Book Value	$1,147,363	BookValueAmt

Buildings BuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$5,465,739	OtherCostOrOtherBasisAmt
Depreciation	$3,623,837	DepreciationAmt
Book Value	$1,841,902	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,427,476	OtherCostOrOtherBasisAmt
Depreciation	$1,462,779	DepreciationAmt
Book Value	$964,697	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$243,105	OtherCostOrOtherBasisAmt
Depreciation	$225,416	DepreciationAmt
Book Value	$17,689	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$3,971,651	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp (2 entries)

DescDesc	Book ValueBookValueAmt	Method ValuationMethodValuationCd
MAKENA PERPETUAL PRIVATE EQUITY FUND	$3,810,912	F
MAKENA PERPETUAL VENTURE CAPITAL FUND	$4,207,362	F

Field	Value	IRS element (for citing)
Total Book Value Securities	$8,018,274	TotalBookValueSecuritiesAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (4 entries)

DescDesc	AmtAmt
CHARITABLE GIFT ANNUITIES	$444,188
CAPITAL LEASE OBLIGATIONS	$108,794
PNC SAHYUN CRUT RESERVE G++ ST	$53,302
ITB VAUD RESERVE	$70,210

Field	Value	IRS element (for citing)
Total Liability	$676,494	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$73,031,620	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$502,498	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$9,240,763	DonatedServicesAndUseFcltsAmt
Recoveries Prior Year Grants	$105,727	RecoveriesPriorYearGrantsAmt
Revenue Not Reported	$9,848,988	RevenueNotReportedAmt
Revenue Subtotal	$63,182,632	RevenueSubtotalAmt
Investment Expenses Not Incld	$241,292	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$241,292	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$63,423,924	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$62,289,890	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$9,240,763	DonatedServicesUseFcltsAmt
Expenses Not Reported	$9,240,763	ExpensesNotReportedAmt
Expenses Subtotal	$53,049,127	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$241,292	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	$4,590	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$245,882	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$53,295,009	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART V, LINE 4:	THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.
PART X, LINE 2:	BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2025, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.
PART XII, LINE 4B - OTHER ADJUSTMENTS:	CHANGE IN PRESENT VALUE OF GRANTS 4,590.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EAST ASIA AND THE PACIFIC	GRANTMAKING	$819,000
EUROPE	GRANTMAKING	$2,125,298
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	GRANTMAKING	$431,595
SOUTH AMERICA	GRANTMAKING	$300,000

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$3,675,893	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$3,675,893	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (16 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
EAST ASIA & THE PACIFIC	MACULAR DEGENERATION RESEARCH BY DAISY YAO SHU, PHD ENTITLED: M2025005N	$409,500	WIRE TRANSFER	$0
EAST ASIA & THE PACIFIC	MACULAR DEGENERATION RESEARCH BY MASAYUKI HATA, PHD ENTITLED: M2025006N	$409,500	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY WILLEM ANNAERT, PHD ENTITLED: A2024033S	$300,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY FRANCES WISEMAN, PHD ENTITLED: A2024040S	$300,000	WIRE TRANSFER	$0
NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.)	ALZHEIMER'S DISEASE RESEARCH BY ISABELLE AUBERT, PHD ENTITLED: A2025018S	$300,000	WIRE TRANSFER	$0
SOUTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY CAROLINA OCHOA-ROSALES, PHD ENTITLED: A2025027S	$300,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY NADER SAFFARI, PHD ENTITLED: A2025022S	$299,217	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY JOHN HARDY, PHD, FRS ENTITLED: A2025012S	$231,239	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY LAURA FUMAGALLI, PHD ENTITLED: A2025008F	$200,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY FEDERICA ANASTASI, PHD ENTITLED: A2025004F	$199,996	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY JOLLE ELISE VERGROESEN, PHD ENTITLED: M2025010F	$182,000	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY PETE WILLIAMS, PHD ENTITLED: G2025006S	$181,181	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	BIRAX RESEARCH FUNDING, ENTITLED: CA2023002	$146,664	WIRE TRANSFER	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY OLAV M. ANDERSEN, PHD ENTITLED: CA2025001	$85,000	WIRE TRANSFER	$0
NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.)	ALZHEIMER'S DISEASE RESEARCH BY MALLAR CHAKRAVARTY, PHD ENTITLED: CA2025002	$85,000	WIRE TRANSFER	$0
NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.)	MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: CA2023003	$46,595	WIRE TRANSFER	$0

Field	Value	IRS element (for citing)
Total501c3 Org	5	Total501c3OrgCnt
Total Other Org	11	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 2:	BEFORE AN INTERNATIONAL GRANT IS AWARDED OR PAID, BRIGHTFOCUS CONFIRMS THAT THE RECIPIENT AND/OR INSTITUTION SUPPORTING THE RESEARCH IS NOT INCLUDED ON THE OFAC (OFFICE OF FOREIGN ASSETS CONTROL) SANCTIONS LIST OR THE INTERNATIONAL BOYCOTT LIST ON THE FEDERAL REGISTER. AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.
PART I, LINE 3:	BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.
PART II, LINE 1:	BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.
PART II, LINE 1, COLUMN (D)	REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY WILLEM ANNAERT, PHD ENTITLED: A2024033S DECODING THE ROLE OF AN ALZHEIMER'S CAUSAL GENE IN DISTINCT BRAIN CELL TYPES. INVESTIGATOR'S SUMMARY: MUTATIONS IN THE GENE ENCODING PRESENILIN2 (PSEN2) CAUSE EARLY ONSET FAMILIAL ALZHEIMER'S DISEASE BUT THUS FAR THIS WAS MAINLY STUDIED IN THE CONTEXT OF A BUILD-UP OF TOXIC AMYLOID AGGREGATES. HOWEVER GIVEN ITS RESTRICTED LOCALIZATION IN DEGRADATIVE COMPARTMENTS, WE HYPOTHESIZE THAT MECHANISMS EXIST LEADING TO DISEASE ONSET THAT MAY DIFFER FROM ITS CLOSE RELATIVE PSEN1. UTILIZING NEW PSEN2 AD MOUSE MODELS AND HUMAN NEURONS/MICROGLIA, WE WILL EMPLOY FUNCTIONAL ASSAYS AND ADVANCED MORPHOLOGICAL STUDIES TO UNRAVEL THE CELL TYPE SPECIFIC CONTRIBUTIONS OF PSEN2 IN AD ETIOPATHOGENESIS. GRANT AWARDED: $300,000, FLEMISH INSTITUTE FOR BIOTECHNOLOGY, GHENT, BELGIUM. REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FRANCES WISEMAN, PHD ENTITLED: A2024040S THE ROLE OF DYRK1A KINASE IN ALZHEIMER'S DISEASE MICROGLIA DIFFERENCES. INVESTIGATOR'S SUMMARY: DOWN SYNDROME IS A GENETIC CONDITION, CAUSED BY AN EXTRA COPY OF CHROMOSOME 21, AND IS ASSOCIATED WITH A GREATLY INCREASED RISK OF DEVELOPING EARLY-ONSET DEMENTIA CAUSED BY ALZHEIMER'S DISEASE. RECENT RESEARCH HAS DEMONSTRATED THE BRAIN'S IMMUNE RESPONSE TO ALZHEIMER'S DISEASE PATHOLOGY DIFFERS IN PEOPLE WHO HAVE DOWN SYNDROME AND THAT THIS MAY CONTRIBUTE TO THE DEVELOPMENT OF DEMENTIA. OUR DATA INDICATE THAT THE CHROMOSOME 21 GENE, DYRK1A MAY CONTRIBUTE TO THIS; HERE WE PROPOSE TO TEST THIS HYPOTHESIS IN A NEW CELLULAR MODEL OF ALZHEIMER'S DISEASE IN THE CONTEXT OF TRISOMY OF CHROMOSOME 21. GRANT AWARDED: $300,000, UNIVERSITY COLLEGE LONDON INSTITUTE OF NEUROLOGY, LONDON, UNITED KINGDOM. REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FEDERICA ANASTASI, PHD ENTITLED: A2025004F PERSONALIZED PROTEOMICS TO UNDERSTAND AND PREDICT ALZHEIMER'S PROGRESSION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) AFFECTS PEOPLE DIFFERENTLY, LEADING TO VARYING RATES OF MEMORY LOSS AND COGNITIVE DECLINE. WHILE BLOOD TESTS CAN HELP DETECT EARLY SIGNS OF AD, THERE'S STILL MUCH TO LEARN ABOUT WHY THESE DIFFERENCES OCCUR. THIS PROJECT FOCUSES ON IDENTIFYING NEW BIOMARKERS TO EXPLAIN WHY INDIVIDUALS EXPERIENCE AD DIFFERENTLY AND PREDICT WHO WILL BE MOST AFFECTED. BY DISCOVERING THESE MARKERS, WE AIM TO DEVELOP PERSONALIZED TOOLS FOR EARLIER INTERVENTION, IMPROVE PREDICTIONS, AND ENHANCE THE RECRUITMENT OF PARTICIPANTS FOR CLINICAL TRIALS. GRANT AWARDED: $199,996, BARCELONABETA BRAIN RESEARCH CENTER, BARCELONA, SPAIN. REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LAURA FUMAGALLI, PHD ENTITLED: A2025008F LEVERAGING HOW THE BRAIN'S IMMUNE CELLS FUEL FRONTOTEMPORAL DEMENTIA. INVESTIGATOR'S SUMMARY: A MUTATION IN THE C9ORF72 GENE IS THE LEADING GENETIC CAUSE OF FTD AND ALS, BUT ITS ROLE IN BRAIN CELL DAMAGE REMAINS UNCLEAR. THE GENE IS HIGHLY ACTIVE IN MICROGLIA, THE BRAIN'S IMMUNE CELLS, WHICH MAY MALFUNCTION DUE TO THIS MUTATION. SINCE UNHEALTHY MICROGLIA CAN WORSEN BRAIN DISEASES, THIS STUDY WILL EXPLORE HOW THE C9ORF72 MUTATION AFFECTS THEM. USING AN INNOVATIVE MODEL THAT MIMICS A BRAIN-LIKE ENVIRONMENT, I WILL ANALYZE HOW THE MUTATION ALTERS MICROGLIAL ACTIVITY AND FUNCTION. THIS RESEARCH COULD REVEAL NOVEL DRUG TARGETS AND DIAGNOSTICS TOOLS. GRANT AWARDED: $200,000, FLANDERS INSTITUTE FOR BIOTECHNOLOGY, ANTWERPEN, BELGIUM. REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOHN HARDY, PHD, FRS ENTITLED: A2025012S A NEW LOOK AT GENETICS USING OLD DATA: ALZHEIMER'S PROGRESSION. INVESTIGATOR'S SUMMARY: WE HAVE SPENT BILLIONS OF DOLLARS AND DECADES STUDYING ALZHEIMER'S DISEASE (AD) BUT HAVE NOT YET FOUND AN EFFECTIVE TREATMENT. MOST ARE BASED ON OUR RESEARCH INTO UNDERSTANDING FACTORS INCREASING THE RISK OF GETTING AD. MODIFICATION OF THOSE FACTORS ARE THEN USED TO SEE IF THE SPEED AT WHICH AD PROGRESSES CAN BE SLOWED DOWN. HOWEVER, THERE IS NO EVIDENCE THAT FACTORS THAT DETERMINE RISK OF GETTING AD ARE THE SAME AS THOSE THAT AFFECT PROGRESSION OF AD! GENETICS CAN TELL US ABOUT BIOLOGY. BY REUSING CLINICAL TRIAL DATA AND THEIR GENETICS, WE CAN SEE WHAT THE BIOLOGY OF PROGRESSION IS. GRANT AWARDED: $231,239, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM. REGION: NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ISABELLE AUBERT, PHD ENTITLED: A2025018S USING ULTRASOUND TO HELP THE BRAIN REBUILD MYELIN IN ALZHEIMER'S. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE AFFECTS BOTH WHITE AND GREY MATTER. THE PREDOMINANT CELLS IN WHITE MATTER, OLIGODENDROCYTES, PRODUCE MYELIN, WHICH INSULATES CELLS TO IMPROVE COMMUNICATION. WHITE MATTER DEFICITS CAN RESULT IN CELL LOSS AND COMMUNICATION BREAKDOWN. IN A PRECLINICAL MODEL OF ALZHEIMER'S DISEASE, WE HAVE DISCOVERED THAT NON-INVASIVE ULTRASOUND WAVES CAN GENERATE NEW OLIGODENDROCYTES THAT MAY BOOST MYELIN PRODUCTION. WITH FUNDING, WE AIM TO DEVELOP THIS INNOVATIVE THERAPY, WHICH HAS THE POTENTIAL TO IMPROVE BRAIN FUNCTION AFFECTED BY ALZHEIMER'S DISEASE, INCLUDING LEARNING AND MEMORY. GRANT AWARDED: $300,000, SUNNYBROOK RESEARCH INSTITUTE, TORONTO, CANADA. REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NADER SAFFARI, PHD ENTITLED: A2025022S CAN ULTRASOUND TRIGGER IMMUNE CELLS TO CLEAR TOXINS IN ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: AS THE POPULATION AGES, ALZHEIMER'S DISEASE CASES ARE INCREASING AND A BUILD-UP IN THE BRAIN OF A HARMFUL PROTEIN, CALLED AMYLOID BETA (A), IS A KEY FACTOR. CURRENT TREATMENTS TO REDUCE A LEVELS ARE COSTLY AND CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING BRAIN BLEEDING. THIS STUDY EXPLORES ULTRASOUND AS A SAFE, NON-INVASIVE WAY TO HELP BRAIN IMMUNE CELLS, CALLED MICROGLIA, CLEAR THESE PROTEINS: ULTRASOUND ACTIVATES MICROGLIA, RESTORING THEIR ABILITY TO CLEAN THE BRAIN, AND THIS PROMISING METHOD COULD OFFER A MORE EFFECTIVE AND AFFORDABLE TREATMENT FOR ALZHEIMER'S. GRANT AWARDED: $299,217, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (1)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp

Organization Business Name OrganizationBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RKD GROUP	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	35 PARKWOOD DRIVE STE 160	AddressLine1Txt
City	HOPKINTON	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	01748	ZIPCd

Field	Value	IRS element (for citing)
Activity	FUNDRAISING AND COMMUNICATIONS CONSULTANT	ActivityTxt
Fundraiser Control Of Funds	0	FundraiserControlOfFundsInd
Gross Receipts	$33,176,193	GrossReceiptsAmt
Retained By Contractor	$1,027,076	RetainedByContractorAmt
Net To Organization	$32,149,117	NetToOrganizationAmt

Field	Value	IRS element (for citing)
Total Gross Receipts	$33,176,193	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,027,076	TotalRetainedByContractorsAmt
Total Net To Organization	$32,149,117	TotalNetToOrganizationAmt
Licensed States	AK	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WV	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	CONCERT FOR CURES	Event1Nm
Gross Receipts Event1	$253,075	GrossReceiptsEvent1Amt
Charitable Contri Event1	$222,435	CharitableContriEvent1Amt
Gross Revenue Event1	$30,640	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$12,862	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$38,560	FoodAndBeverageEvent1Amt
Entertainment Event1	$13,342	EntertainmentEvent1Amt
Other Direct Expenses Event1	$22,484	OtherDirectExpensesEvent1Amt
Gross Receipts Total	$253,075	GrossReceiptsTotalAmt
Charitable Contributions Tot	$222,435	CharitableContributionsTotAmt
Gross Revenue Total Events	$30,640	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$12,862	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$38,560	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$13,342	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$22,484	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$87,248	DirectExpenseSummaryEventsAmt
Net Income Summary	-$56,608	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE G, PART I, LINE 2B, COLUMN (V)	FormAndLineReferenceDesc
Explanation	IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $1,243,296 PER YEAR OF WHICH $636,600 HAS BEEN ALLOCATED UNDER PART IX, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (57 entries)

Address Line1USAddress/AddressLine1Txt	Address Line2USAddress/AddressLine2Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt
WILLIAM MARSH RICE UNIVERSITY
6100 MAIN ST BIOSCIENCE RESEARCH	COLLABORATIVE	HOUSTON	TX	77030	741109620	501(C)(3)	$409,500	$0	MACULAR DEGENERATION RESEARCH BY JERZY SZABLOWSKI, PHD ENTITLED: M2025001N
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
608 STANTON L YOUNG BLVD		OKLAHOMA CITY	OK	73104	731563627	501(C)(3)	$409,500	$0	MACULAR DEGENERATION RESEARCH BY ANA J CHUCAIR-ELLIOTT, PHD ENTITLED: M2025002N
LELAND STANFORD JUNIOR UNIVERSITY
BYERS EYE INSTITUTE 2452 WATSON	COURT	PALO ALTO	CA	94303	941156365	501(C)(3)	$409,500	$0	MACULAR DEGENERATION RESEARCH BY CHARLES DEBOER, MD, PHD ENTITLED: M2025004N
LELAND STANFORD JUNIOR UNIVERSITY
300 CAMPUS DRIVE GRANT BUILDING	OPHTHALMOLOGY DEPT	STANFORD	CA	94305	941156365	501(C)(3)	$409,500	$0	MACULAR DEGENERATION RESEARCH BY MOHAJEET BALVEER BHUCKORY, PHD ENTITLED: M2025007N
NATIONAL EYE INSTITUTE NIH
10 CENTER DRIVE RM 10N116 FLOOR 10	BLD 10	BETHESDA	MD	20852	520858115	501(C)(3)	$408,701	$0	MACULAR DEGENERATION RESEARCH BY RUCHI SHARMA, PHD ENTITLED: M2025003N
BETH ISRAEL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUE		BOSTON	MA	02215	042103881	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY PETER FRIED, PHD ENTITLED: A2024034S
LELAND STANFORD JUNIOR UNIVERSITY
1201 WELCH RD		PALO ALTO	CA	94305	941156365	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY AMIRA LATIF HERNANDEZ, PHD ENTITLED: A2024035S
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE		LA JOLLA	CA	92093	956006144	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JEROME MERTENS, PHD ENTITLED: A2024036S
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
4333 BROOKLYN AVE NE		SEATTLE	WA	98195	916001537	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JUSTIN MILLER, PHD ENTITLED: A2024037S
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE		LA JOLLA	CA	92093	956006144	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JOHANNES SCHLACHETZKI, MD ENTITLED: A2024038S
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
789 S LIMESTONE TODD 565		LEXINGTON	KY	40536	616033693	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY LINDA VAN ELDIK, PHD ENTITLED: A2024039S
VANDERBILT UNIVERSITY MEDICAL CENTER
2213 GARLAND AVE		NASHVILLE	TN	37232	352528741	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY MONICA SANTISTEBAN, PHD ENTITLED: A2025011S
THE J DAVID GLADSTONE INSTITUTES
1650 OWENS ST		SAN FRANCISCO	CA	94158	237203666	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY KATERINA AKASSOGLOU, PHD ENTITLED: A2025013S
MASSACHUSETTS GENERAL HOSPITAL
114 SIXTEENTH ST		CHARLESTOWN	MA	02129	042697983	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY KSENIA KASTANENKA, PHD ENTITLED: A2025014S
COLUMBIA UNIVERSITY
622 W 168TH ST		NEW YORK	NY	10025	135598093	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JAE-EUN MILLER, PHD ENTITLED: A2025016S
NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS
300 EAST SUPERIOR STREETTARRY 7-758		CHICAGO	IL	60611	362167817	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JUSTYNA DOBROWOLSKA ZAKARIA, PHD ENTITLED: A2025019S
WASHINGTON UNIVERSITY IN STLOUIS
CAMPUS BOX 1054 ONE BROOKINGS DRIVE		ST LOUIS	MO	63130	430653611	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY CYRIL POTTIER, PHD ENTITLED: A2025020S
RESEARCH FOUNDATION OF SUNY - UNIVERSITY AT ALBANY
OFFICE FOR SPONSORED PROGRAMS/MSC	312 1400 WASHINGTON AVENUE	ALBANY	NY	12222	141368361	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY DAMIAN ZULOAGA, PHD ENTITLED: A2025021S
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
3 E 101ST ST		NEW YORK	NY	10029	136171197	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JACK HUMPHREY, PHD ENTITLED: A2025024S
THE OHIO STATE UNIVERSITY
460 W 12TH AVE		COLUMBUS	OH	43210	316025986	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY HONGJUN FU, PHD ENTITLED: A2025025S
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
115 MASON FARM RD 6109C	NEUROSCIENCE RESEARCH BUILDING CB 7	CHAPEL HILL	NC	27599	566001393	501(C)(3)	$300,000	$0	ALZHEIMER'S DISEASE RESEARCH BY TODD J. COHEN, PHD ENTITLED: A2025026S
INDIANA UNIVERSITY
340 WEST 10TH STREET		INDIANAPOLIS	IN	46202	356001673	501(C)(3)	$299,843	$0	ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHARMD, PHD ENTITLED: A2025015S
BETH ISRAEL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUE		BOSTON	MA	02115	042103881	501(C)(3)	$299,838	$0	ALZHEIMER'S DISEASE RESEARCH BY FENG TIAN, PHD ENTITLED: A2025017S
INDIANA UNIVERSITY
NB BUILDING 320 W 15TH ST 414		INDIANAPOLIS	IN	46202	356001673	501(C)(3)	$297,517	$0	ALZHEIMER'S DISEASE RESEARCH BY REBECCA WALLINGS, DPHIL ENTITLED: A2025023S
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD		JACKSONVILLE	FL	32224	593337028	501(C)(3)	$235,163	$0	ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021010
EMORY UNIVERSITY
1599 CLIFTON ROAD NE 4TH FLOOR		ATLANTA	GA	30322	580566256	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JOSHNA GADHAVI, PHD ENTITLED: A2024029F
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
1550 4TH ST ROCK HALL 381		SAN FRANCISCO	CA	94143	946036493	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY DONG KYU KIM, PHD ENTITLED: A2024030F
WASHINGTON UNIVERSITY IN STLOUIS
4370 DUNCAN AVE		ST LOUIS	MO	63110	430653611	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY ASHISH SHARMA, PHD ENTITLED: A2024031F
COLUMBIA UNIVERSITY
3227 BROADWAY L-5-055		NEW YORK	NY	10027	135598093	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY EMILIANO ZAMPONI, PHD ENTITLED: A2024032F
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MS BCM ROOM N930		HOUSTON	TX	77030	741613878	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY OMAR PEA-RAMOS, PHD ENTITLED: A2025002F
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1425 MADISON AVENUE FLOOR 9 ROOM	9-02C	NEW YORK	NY	10029	136171197	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY MARCOS SCHAAN PROFES, PHD ENTITLED: A2025003F
BRIGHAM AND WOMEN'S HOSPITAL INC
60 FENWOOD ROAD		BOSTON	MA	02115	042312909	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY SARAH ELISE HEUER, PHD ENTITLED: A2025005F
WASHINGTON UNIVERSITY IN STLOUIS
4370 DUNCAN AVE		SAINT LOUIS	MO	63110	430653611	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JOSHUA EMMERSON, PHD ENTITLED: A2025006F
UNIVERSITY OF CALIFORNIA IRVINE
UNIVERSITY OF CALIFORNIA IRVINE	3014 GROSS HALL	IRVINE	CA	92697	952226406	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY GHAZALEH ESKANDARI-SEDIGHI, PHD ENTITLED: A2025007F
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
10010 NORTH TORREY PINES ROAD		LA JOLLA	CA	92037	952160097	501(C)(3)	$200,000	$0	ALZHEIMER'S DISEASE RESEARCH BY JOSEPH HERDY, PHD ENTITLED: A2025010F
UNIVERSITY OF PITTSBURGH
BIOMEDICAL SCIENCE TOWER 3 3501	FIFTH AVENUE	PITTSBURGH	PA	15213	250965591	501(C)(3)	$199,724	$0	ALZHEIMER'S DISEASE RESEARCH BY JR-JIUN LIOU, PHD ENTITLED: A2025009F
MAYO CLINC ROCHESTER
200 FIRST ST SW		ROCHESTER	MN	55905	416011702	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY GAVIN RODDY, MD, PHD ENTITLED: G2025001S
UNIVERSITY OF CALIFORNIA SAN DIEGO
9452 MEDICAL CENTER DRIVE		LA JOLLA	CA	92037	956006144	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY KARL JONAS WAHLIN, PHD ENTITLED: G2025002S
UNIVERSITY OF WISCONSIN-MADISON
DEPARTMENT OF OPHTHALMOLOGY		MADISON	WI	53706	396006492	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY ROB NICKELLS, PHD ENTITLED: G2025003S
DUKE UNIVERSITY SCHOOL OF MEDICINE
2200 W MAIN STREET SUITE 710		DURHAM	NC	27705	560532129	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY DAN STAMER, PHD ENTITLED: G2025004S
UNIVERSITY OF SOUTHERN CALIFORNIA
DEPARTMENT OF OPHTHALMOLOGY 1450	SAN PABLO STREET 4TH FLOOR	LOS ANGELES	CA	90033	951642394	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY BENJAMIN XU, MD, PHD ENTITLED: G2025005S
THE SCHEPENS EYE RESEARCH INSTITUTE INC
20 STANIFORD STREET		BOSTON	MA	02114	042129889	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY TATJANA JAKOBS, MD ENTITLED: G2025008S
UNIVERSITY OF CALIFORNIA IRVINE
324 ALDRICH HALL		IRVINE	CA	92697	952226406	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD ENTITLED: G2025009S
UNIVERSITY OF WISCONSIN-MADISON
DEPARTMENT OF OPHTHALMOLOGY VISUAL	SCIENCES 3375 MEDICAL SCIENCES CENT	MADISON	WI	53706	396006492	501(C)(3)	$182,000	$0	NATIONAL GLAUCOMA RESEARCH BY COLLEEN MCDOWELL, PHD ENTITLED: G2025010S
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
1550 4TH STREET ROOM 445		SAN FRANCISCO	CA	94158	946036493	501(C)(3)	$182,000	$0	MACULAR DEGENERATION RESEARCH BY VALENCIA FERNANDES, PHD ENTITLED: M2025008F
DUKE UNIVERSITY SCHOOL OF MEDICINE
2351 ERWIN RD AERI 3000		DURHAM	NC	27705	560532129	501(C)(3)	$182,000	$0	MACULAR DEGENERATION RESEARCH BY DR. NOBUHIKO SHIRAKI, PHD ENTITLED: M2025011F
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE		LA JOLLA	CA	92093	956006144	501(C)(3)	$182,000	$0	MACULAR DEGENERATION RESEARCH BY JAESOO JUNG, PHD ENTITLED: M20250013F
GOOD SAMARITAN FOUNDATION
1225 NE 2ND AVENUE 3RD FLOOR		PORTLAND	OR	97232	237017276	501(C)(3)	$181,798	$0	NATIONAL GLAUCOMA RESEARCH BY BRAD FORTUNE, OD, PHD ENTITLED: G2025007S
UNIVERSITY OF IDAHO
875 PERIMETER DRIVE MS 3020		MOSCOW	ID	83844	826000945	501(C)(3)	$180,864	$0	MACULAR DEGENERATION RESEARCH BY ASHLEY FARRE, PHD ENTITLED: M2025012F
INDIANA UNIVERSITY
635 BARNHILL DRIVE		INDIANAPOLIS	IN	46202	356001673	501(C)(3)	$180,523	$0	ALZHEIMER'S DISEASE RESEARCH BY ANLLELY FERNANDEZ, PHD ENTITLED: A2025001F
THE FISHER CENTER FOR ALZHEIMERS DISEASE RESEARCH
FDR STATION PO BOX 220		NEW YORK	NY	10150	133859563	501(C)(3)	$133,597	$0	ALZHEIMER'S DISEASE RESEARCH FUNDING
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION
1001 MAYPORT ROAD PO BOX 331076		ATLANTIC BEACH	FL	32233	862907045	501(C)(3)	$115,000	$0	ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021011
MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM
315 SIGMA DRIVE		SUMMERVILLE	SC	29486	474960128	501(C)(3)	$100,000	$0	ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2025003
JOHNS HOPKINS UNIVERSITY
3910 KESWICK ROAD N4327B		BALTIMORE	MD	21211	520595110	501(C)(3)	$75,000	$0	RRESTORE CONSORTIUM RESEARCH FUNDING AND TRAVEL GRANTS FOR CONFERENCE ATTENDEES
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION
1201 11TH AVE SOUTH SUITE 300		BIRMINGHAM	AL	35205	630983733	501(C)(3)	$75,000	$0	HELEN KELLER PRIZE FOR VISION RESEARCH FUNDING
INTERNATIONAL SOCIETY FOR EYE RESEARCH
655 BEACH STREET		SAN FRANCISCO	CA	94109	510171667	501(C)(3)	$30,000	$0	TRAVEL GRANTS FOR CONFERENCE ATTENDEES AND RESEARCH SPONSORSHIP
ARVO FOUNDATION FOR EYE RESEARCH
1801 ROCKVILLE PIKE SUITE 400		ROCKVILLE	MD	20852	522322462	501(C)(3)	$15,240	$0	TRAVEL GRANTS FOR CONFERENCE ATTENDEES

Field	Value	IRS element (for citing)
Total501c3 Org	57	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail (8 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 2:	AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.
PART II, LINE 1(H)	NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSHNA GADHAVI, PHD ENTITLED: A2024029F ASSESSING THE IMPACT OF BLOOD-BRAIN BARRIER DYSFUNCTION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: BLOOD-BRAIN BARRIER (BBB) BREAKDOWN HAS BEEN OBSERVED IN VARIOUS NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE. IN A HEALTHY BRAIN, THE BBB DOES NOT ALLOW TRANSPORTATION OF PROTEINS OR LARGE MOLECULES INTO THE BRAIN. HOWEVER, DUE TO BBB DYSFUNCTION, ENHANCED PERMEABILITY OF PLASMA-DERIVED PROTEINS CAN BE OBSERVED IN DIFFERENT PARTS OF BRAIN REGIONS, AND MAY LEAD TO NEUROTOXICITY, NEUROINFLAMMATION, AND OXIDATIVE STRESS. THIS PROJECT WILL IDENTIFY NOVEL BIOMARKERS AND KEY TARGETS FOR BBB BREAKDOWN AND EXPLORE HOW IT MAY CONTRIBUTE TO ALZHEIMER'S DIAGNOSIS AND PROGRESSION. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DONG KYU KIM, PHD ENTITLED: A2024030F DEFINING THE IMPACT OF CYTOKINE SIGNALING IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: IMMUNE SIGNALS REGULATE BRAIN HOMEOSTASIS AND ARE ALSO A MAJOR DRIVER OF ALZHEIMER'S DISEASE PATHOLOGY. THIS STUDY WILL INVESTIGATE HOW ASTROCYTE-MICROGLIA CROSSTALK VIA IL-33 CYTOKINE IMPACTS ALZHEIMER'S DISEASE PATHOLOGY AND BEHAVIOR. THIS WORK WILL DETERMINE THE MECHANISTIC IMPACT OF A KEY IMMUNE PATHWAY IN AD PATHOLOGY AND SUGGEST THE NOVEL HYPOTHESIS THAT ECM DISRUPTION IS LINKED TO AD PATHOLOGY. NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ASHISH SHARMA, PHD ENTITLED: A2024031F CIRCADIAN RHYTHM DISRUPTION AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THIS STUDY INVESTIGATES HOW DISRUPTIONS TO CIRCADIAN RHYTHMS, COMMON IN AGING AND ALZHEIMER'S DISEASE, IMPACT DISEASE PROGRESSION USING A MOUSE MODEL OF CHRONIC JETLAG (CJL). RESEARCHERS AIM TO UNDERSTAND HOW CJL AFFECTS ALZHEIMER'S MARKERSAMYLOID PLAQUES AND TAU PROTEIN ACCUMULATION. INVESTIGATING THE CONNECTION BETWEEN CIRCADIAN DISRUPTION, GLIAL FUNCTION, AND ALZHEIMER'S-RELATED CHANGES MAY REVEAL THERAPEUTIC STRATEGIES, OFFERING NOVEL APPROACHES TO DISEASE PREVENTION. NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY EMILIANO ZAMPONI, PHD ENTITLED: A2024032F MECHANISMS OF INHIBITORY NEURON VULNERABILITY TO ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: INHIBITORY INTERNEURONS, ONE OF THE KEY PLAYERS IN HUMAN COGNITIVE PROCESSES, ARE AMONG THE FIRST NEURONAL POPULATIONS AFFECTED BY AD ONSET. I PROPOSE THEIR ELEVATED ENERGY CONSUMPTION RATES MAKE THESE INTERNEURONS MORE VULNERABLE TO AD. USING MULTIPLE INNOVATIVE APPROACHES, I WILL INVESTIGATE THREE FUNDAMENTAL ASPECTS UNDERLYING INHIBITORY INTERNEURON VULNERABILITY TO AD. BY COMPLETING THE AIMS OF MY PROPOSAL, I EXPECT TO GAIN NEW INSIGHTS INTO THE PATHOLOGICAL BASIS OF THIS SOCIALLY DEVASTATING NEUROLOGICAL CONDITION AND TO DEVELOP NOVEL THERAPEUTIC APPROACHES. NAME OF ORGANIZATION OR GOVERNMENT: BETH ISRAEL DEACONESS MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER FRIED, PHD ENTITLED: A2024034S TREATING INSOMNIA IN MILD COGNITIVE IMPAIRMENT. INVESTIGATOR'S SUMMARY: MANY PEOPLE WITH MILD COGNITIVE IMPAIRMENT (MCI) EXPERIENCE SYMPTOMS OF INSOMNIA, SUCH AS DIFFICULTY FALLING OR STAYING ASLEEP, WHICH CAN SPEED COGNITIVE DECLINE AND WORSEN QUALITY OF LIFE. WE PROPOSE TO TEST A NOVEL INTERVENTION TO IMPROVE SLEEP AND COGNITION IN PERSONS WITH MCI THAT COMBINES NONINVASIVE NEUROMODULATION WITH TRANSCRANIAL MAGNETIC STIMULATION WITH AN INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA PROGRAM. IF SUCCESSFUL, THIS APPROACH WILL MEET THE NEED FOR AN EFFICACIOUS, NON-PHARMACOLOGIC, AND ACCESSIBLE THERAPY FOR PERSONS WITH MCI AND INSOMNIA. NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY AMIRA LATIF HERNANDEZ, PHD ENTITLED: A2024035S TARGETING BRAIN CELL MISCOMMUNICATION TO RESTORE MEMORY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN'S ABILITY TO ADAPT AND CHANGE, KNOWN AS SYNAPTIC PLASTICITY, REQUIRES THE EXPRESSION OF SPECIFIC GENES AND PROTEINS IN DIFFERENT BRAIN CELLS, NEURONS AND ASTROCYTES, WHICH IS AFFECTED IN BRAIN DISORDERS LIKE ALZHEIMER'S. IN ORDER TO FIND POTENTIAL THERAPEUTIC STRATEGIES TO RECOVER SYNAPTIC PLASTICITY, CELL COMMUNICATION, AND TO IMPROVE MEMORY IN ALZHEIMER'S, WE WILL USE ADVANCED TECHNIQUES IN MOUSE MODELS AND LAB-GROWN HUMAN CELLS WITH ALZHEIMER'S-LIKE PATHOLOGY. OUR RESULTS WILL CONTRIBUTE TO THE DEVELOPMENT OF IMPROVED TREATMENTS FOR PATIENTS WITH SYNAPTIC PLASTICITY DISORDERS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JEROME MERTENS, PHD ENTITLED: A2024036S CANCER-LIKE METABOLIC CHANGES IN ALZHEIMER'S DISEASE NEURONS. INVESTIGATOR'S SUMMARY: THIS RESEARCH FOCUSES ON HOW METABOLIC CHANGES IMPACT GENE EXPRESSION AND PROTEIN MODIFICATIONS IN ALZHEIMER'S DISEASE (AD). USING NEURONS FROM AD PATIENTS, WE'VE IDENTIFIED DISRUPTIONS IN METABOLIC PATHWAYS LEADING TO ABNORMAL GENE PROCESSING. OUR STUDY AIMS TO UNDERSTAND HOW THESE CHANGES CONTRIBUTE TO KEY AD FEATURES, SUCH AS TAU TANGLE FORMATION. BY UNDERSTANDING UPSTREAM METABOLIC PATHWAYS OF AD PATHOLOGY, WE AIM TO IDENTIFY POTENTIAL INTERVENTION TARGETS TO RESCUE THE LOSS OF SYNAPTIC FUNCTION AND PREVENT NEURONAL CELL DEATH. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JUSTIN MILLER, PHD ENTITLED: A2024037S EXPLORING RURAL HEALTH DISPARITIES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THERE IS EMERGING EVIDENCE THAT OLDER ADULTS LIVING IN RURAL COMMUNITIES ARE AT INCREASED RISK FOR ALZHEIMER'S DISEASE (AD); HOWEVER, RURAL COMMUNITIES HAVE BEEN SEVERELY UNDERREPRESENTED IN AD RESEARCH, AND THE FACTORS THAT MAY BE CONTRIBUTING TO THESE URBAN-RURAL DISPARITIES ARE UNCLEAR. OUR LONG-TERM GOAL IS TO FULLY CHARACTERIZE COGNITIVE AGING AND VALIDATE AD-SPECIFIC BIOMARKERS AMONG RURAL-DWELLING OLDER ADULTS. THIS PROJECT WILL ENRICH THE BIOMARKER CHARACTERIZATION OF OUR RURAL COHORT AND FACILITATE IDENTIFICATION OF THE MOST VIABLE BLOOD MARKERS FOR USE IN RURAL-DWELLING OLDER ADULTS.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOHANNES SCHLACHETZKI, MD ENTITLED: A2024038S REGULATION OF MICROGLIA PHENOTYPES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS DEFINED BY THE ACCUMULATION OF HARMFUL PROTEINS IN THE BRAIN. MICROGLIA, THE IMMUNE CELLS OF THE BRAIN, PLAY A KEY ROLE IN THIS PROCESS, BUT THE MOLECULAR MECHANISMS THAT LEAD TO DISTINCT PHENOTYPES ARE UNCLEAR. THIS STUDY WILL USE ADVANCED TECHNIQUES TO ISOLATE AND ANALYZE MICROGLIA, REVEALING HOW THEY CONTRIBUTE TO DISEASE AND IDENTIFYING NEW TARGETS FOR DEVELOPING EFFECTIVE TREATMENTS. WE WILL TEST THE HYPOTHESIS THAT SPECIFIC GROUPS OF PROTEIN FAMILIES (MIT/TFE AND AP-1), ARE RESPONSIBLE FOR CONTROLLING THE GENES THAT MICROGLIA TURN ON OR OFF IN ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LINDA VAN ELDIK, PHD ENTITLED: A2024039S DYSREGULATED ASTROCYTE P38, BRAIN INFLAMMATION, AND ALZHEIMER'S PATHOLOGY. INVESTIGATOR'S SUMMARY: ASTROCYTES, THE MOST ABUNDANT GLIAL CELL TYPE IN THE BRAIN, BECOME ABNORMALLY ACTIVATED EARLY IN ALZHEIMER'S DISEASE (AD) AND CAN LEAD TO DETRIMENTAL BRAIN INFLAMMATION AND NERVE CELL DAMAGE. THE P38 MAPK DRIVES INFLAMMATION IN MICROGLIA BUT ITS ROLE IN ASTROCYTES IS UNDERSTUDIED. OUR PROJECT WILL USE NOVEL MOUSE MODELS AND WELL-CHARACTERIZED HUMAN BIOSPECIMENS TO DEFINE THE POTENTIAL LINKAGE BETWEEN ASTROCYTE P38, NEUROINFLAMMATION, AND AD NEUROPATHOLOGIC CHANGE, THUS PROVIDING NEW INSIGHT INTO MECHANISMS BY WHICH ABNORMAL ASTROCYTE ACTIVATION IN AD CONTRIBUTES TO DISEASE PROGRESSION. NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANLLELY FERNANDEZ, PHD ENTITLED: A2025001F LINKING PLAQUE SHAPES TO AMYLOID STRUCTURES IN ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER DISEASE (AD) IS MARKED BY ABNORMAL DEPOSITS OF AMYLOID- (A) AND TAU PROTEINS IN THE BRAIN, LEADING TO MEMORY LOSS AND COGNITIVE DECLINE. USING CUTTING-EDGE CRYO-ELECTRON MICROSCOPY, WE AIM TO STUDY THE STRUCTURES OF A IN DIFFERENT PLAQUE TYPES AND BRAIN REGIONS. OUR RESEARCH FOCUSES ON UNDERSTANDING HOW THESE STRUCTURAL VARIATIONS CONTRIBUTE TO DISEASE PROGRESSION, ESPECIALLY IN CASES LINKED TO GENETIC RISK FACTORS LIKE APOEE4. THIS WORK COULD UNCOVER NEW DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS, ADVANCING EFFORTS TO COMBAT AD AND RELATED DISORDERS. NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OMAR PEA-RAMOS, PHD ENTITLED: A2025002F THE ASTROCYTE CELL SURFACE PROTEOME IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: CELL SURFACE PROTEINS (CSPS) HELP CELLS COMMUNICATE AND RESPOND TO THEIR ENVIRONMENT, MAKING THEM KEY DRUG TARGETS. WE PERFORMED CSP PROFILING OF MOUSE ASTROCYTES DURING A-AMYLOID PLAQUE BUILDUP AND IDENTIFIED CD44 AS A TOP CANDIDATE. WE FOUND THAT WHEN CD44 BINDS TO ITS LIGAND OPN, ASTROCYTES TRIGGER LIPID ACCUMULATION WHILE MICE LACKING CD44 SHOW REDUCED INFLAMMATION. BY STUDYING CD44 IN LIVE MICE AND CULTURED ASTROCYTES, WE AIM TO UNCOVER ITS ROLE IN AD AND EXPLORE ITS POTENTIAL AS A THERAPEUTIC TARGET. NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARCOS SCHAAN PROFES, PHD ENTITLED: A2025003F THE ROLE OF JADE1 IN TAUOPATHY. INVESTIGATOR'S SUMMARY: TAUOPATHIES, SUCH AS ALZHEIMER'S DISEASE, RESULT FROM THE TOXIC AGGREGATION OF TAU PROTEINS, BUT THE EXACT PROCESS REMAINS UNCLEAR. WE ARE INVESTIGATING JADE1, A PROTEIN THAT SPECIFICALLY BINDS TOXIC TAU, TO DETERMINE IF IT PREVENTS AGGREGATION OR PROMOTES CLEARANCE VIA CELLULAR PATHWAYS LIKE AUTOPHAGY. USING ADVANCED CELLULAR MODELS, INCLUDING ONE THAT USES LIGHT TO CONTROL TAU BEHAVIOR, OUR RESEARCH AIMS TO UNCOVER HOW JADE1 WORKS AND EXPLORE ITS POTENTIAL AS A TARGET FOR FUTURE TREATMENTS. NAME OF ORGANIZATION OR GOVERNMENT: BRIGHAM AND WOMEN'S HOSPITAL, INC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SARAH ELISE HEUER, PHD ENTITLED: A2025005F DETERMINING THE CELLULAR IMPACTS OF ABCA7 MUTATIONS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: GENETICS PLAYS A KEY ROLE IN GOVERNING ALZHEIMER'S DISEASE (AD) RISK, WITH MANY MUTATIONS LINKED TO LIPID BIOLOGY PROTEINS. ABCA7 IS A LIPID TRANSPORTER AND HAS SEVERAL AD RISK MUTATIONS, SOME FOUND EXCLUSIVELY IN INDIVIDUALS OF AFRICAN ANCESTRY. HOWEVER, THE EFFECTS OF THESE MUTATIONS REMAIN UNCLEAR DUE TO THE HISTORICAL LACK OF DIVERSE REPRESENTATION IN RESEARCH STUDIES. USING MODELS OF LIVING BRAIN CELLS DERIVED FROM HUMANS THAT HARBOR THESE MUTATIONS, I WILL STUDY HOW MODIFYING ABCA7 ALTERS PROTEINS, LIPIDS, AND CELL FUNCTION, PAVING THE WAY FOR INCLUSIVE, PERSONALIZED AD THERAPIES. NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSHUA EMMERSON, PHD ENTITLED: A2025006F TARGETING THE ADAPTIVE IMMUNITY TO PREVENT ALZHEIMER'S BRAIN DEGENERATION. INVESTIGATOR'S SUMMARY: NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) INVOLVE THE BUILDUP OF TAU PROTEINS AND SIGNIFICANT BRAIN DEGENERATION. THIS TAU-MEDIATED DAMAGE IS MAINLY DRIVEN BY INFLAMMATION IN THE BRAIN, WITH RECENT EVIDENCE OF INFILTRATING T-LYMPHOCYTES (T-CELLS) BEING ESSENTIAL TO THIS PROCESS. THIS PROJECT WILL APPLY MULTIDISCIPLINARY APPROACHES TO DETERMINE THE CANDIDATE SIGNALING PATHWAY(S) RESPONSIBLE FOR ATTRACTING T-CELLS TO THE BRAIN IN DISEASE, AND TO BLOCK T-CELL INFILTRATION AS TO PREVENT SUBSEQUENT TAU-MEDIATED BRAIN DEGENERATION IN A GENETICALLY MODIFIED MOUSE MODEL. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GHAZALEH ESKANDARI-SEDIGHI, PHD ENTITLED: A2025007F UNDERSTANDING THE ROLE OF BRAIN IMMUNE CELLS IN PROTECTION AGAINST ALZHEIMER'S. INVESTIGATOR'S SUMMARY: UNDERSTANDING HOW ALZHEIMER'S DISEASE (AD) IS FORMED IS CHALLENGING DUE TO THE COMPLEX, MULTIFACETED NATURE OF THE DISEASE. IT IS KNOWN NOW THAT THE HERITABILITY OF AD IS OVER 60%. SO, UNDERSTANDING THE DISEASE MECHANISM, CAN BE ACHIEVED BY EXPLORING THESE HEREDITARY ELEMENTS IN PATIENTS VS. HEALTHY INDIVIDUALS. OF NOTE, SOME RARE HEREDITARY FACTORS TURN OUT TO BE PROTECTIVE AND CAN PROVIDE PROTECTION AGAINST AD. TAKING ADVANTAGE OF NOVEL, MULTI-FACETED STEM CELL MODELS, WE WILL STUDY APOE3 CHRISTCHURCH AS ONE OF SUCH RARE, RESILIENT FACTORS, WITH SPECIFIC FOCUS ON BRAIN RESIDENT IMMUNE CELLS.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PITTSBURGH (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JR-JIUN LIOU, PHD ENTITLED: A2025009F NEUROIMAGING AND NEUROPATHOLOGY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: WHY DO INDIVIDUALS WITH DOWN SYNDROME DEVELOP ALZHEIMER'S DISEASE DECADES EARLIER THAN THE GENERAL POPULATION? THIS PROPOSAL WILL USE HIGH-RESOLUTION IMAGING AND POSTMORTEM BRAIN SAMPLES FROM WELL-CHARACTERIZED COHORTS OF ADULTS WITH DOWN SYNDROME AND LATE-ONSET ALZHEIMER'S DISEASE. BY IDENTIFYING IMAGING BIOMARKERS AND CLARIFYING EARLY DISEASE MECHANISMS, WE AIM TO ADVANCE UNDERSTANDING OF ALZHEIMER'S IN DOWN SYNDROME, PROMOTE INCLUSIVE RESEARCH, AND GUIDE EFFECTIVE INTERVENTIONS TO IMPROVE DIAGNOSTICS AND TREATMENT STRATEGIES. NAME OF ORGANIZATION OR GOVERNMENT: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOSEPH HERDY, PHD ENTITLED: A2025010F BLOCKING JUMPING GENES TO STOP BRAIN INFLAMMATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS A FATAL NEURODEGENERATIVE DISEASE WITH NO AVAILABLE CURES. BY GENERATING PATIENT SPECIFIC INDUCED NEURONS (INS), WE FOUND THAT THERE IS A SMALL POPULATION OF INFLAMMATORY NEURONS THAT COULD BE TARGETED TO TREAT AD INSTEAD OF STRATEGIES THAT AFFECT THE ENTIRE BRAIN. HOWEVER, HOW THESE NEURONS BECOME INFLAMMATORY, AND THEREFORE WAYS TO INTERVENE ARE CURRENTLY UNKNOWN. IN THIS PROJECT, WE DEEPLY CHARACTERIZE A PROMISING GENETIC TARGET DRIVING INFLAMMATION, AND ASSESS IF BLOCKING ITS ACTIVITY IS A CANDIDATE FOR REVERSING HALLMARKS OF AD. NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSITY MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MONICA SANTISTEBAN, PHD ENTITLED: A2025011S UNDERSTANDING THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE RENIN ANGIOTENSIN SYSTEM MAY PLAY AN IMPORTANT ROLE IN THE PROGRESSION OF PATHOLOGY IN ALZHEIMER'S DISEASE. IN THIS PROPOSAL, WE WILL LOOK AT THE CHOROID PLEXUS, A SMALL TISSUE WITHIN THE BRAIN THAT MAKES THE CEREBROSPINAL FLUID, AS A NOVEL SOURCE CONTRIBUTING TO THE LOCAL BRAIN RENIN ANGIOTENSIN SYSTEM AND COGNITIVE DECLINE IN AD. SINCE THERE ARE LIKELY A LOT MORE CHANGES HAPPENING IN THE CHOROID PLEXUS OTHER THAN THE RENIN ANGIOTENSIN SYSTEM, WE WILL ALSO ESTABLISH A COMPREHENSIVE DATABASE OF THE TRANSCRIPTIONAL CHANGES IN THE CHOROID PLEXUS IN AD TO SERVE AS A TOOL FOR FUTURE DISCOVERY. NAME OF ORGANIZATION OR GOVERNMENT: THE J. DAVID GLADSTONE INSTITUTES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KATERINA AKASSOGLOU, PHD ENTITLED: A2025013S UNRAVELING THE TRIGGERS TO MYELIN DAMAGE IN IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MYELIN DAMAGE HAS EMERGED AS A KEY PLAYER TO ALZHEIMER'S DISEASE (AD). HOWEVER, THE TRIGGERS OF MYELIN PATHOLOGY IN AD REMAIN LARGELY UNKNOWN. FIBRINOGEN, A BLOOD CLOTTING PROTEIN DEPOSITED IN AD BRAIN IS A POTENT INDUCER OF NEUROTOXIC INFLAMMATION AND INHIBITOR OF MYELIN REPAIR. WE WILL DETERMINE THE ROLE OF FIBRINOGEN ON MYELIN-FORMING CELLS IN AD MICE WITH STATE-OF-THE-ART IMAGING, MULTIOMIC TECHNOLOGIES, AND BEHAVIORAL ANALYSIS OF LEARNING AND MEMORY IN AD MICE, AS WELL AS TESTING PHARMACOLOGIC TREATMENTS PROMOTING REMYELINATION. NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KSENIA KASTANENKA, PHD ENTITLED: A2025014S A SLEEPING PILL FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS A MEMORY DISORDER WITHOUT AN EFFECTIVE CURE. DISRUPTIONS IN BRAIN ACTIVITY ASSOCIATED WITH SLEEP AND MEMORY IMPAIRMENTS ALZHEIMER'S PATIENTS EXPERIENCE COULD HOLD THE KEY TO DEVELOPMENT OF EFFECTIVE THERAPEUTIC STRATEGIES. SINCE ALZHEIMER'S PATIENTS SUFFER FROM SLEEP DISTURBANCES, ADMINISTRATION OF FDA-APPROVED SLEEPING PILLS COULD RESTORE THEIR SLEEP AND SLOW DISEASE PROGRESSION. THUS, WE WILL ADMINISTER PROVEN AND SAFE SLEEPING PILLS IN A MOUSE MODEL. THE RESULTS WILL INDICATE WHETHER SLEEPING PILLS COULD BE EFFECTIVE AT SLOWING ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHARMD, PHD ENTITLED: A2025015S HOW DOES NIACIN PRODUCTION IN THE GUT ASSOCIATED TO ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE HAS BEEN CORRELATED WITH IMBALANCES IN GUT BACTERIA, HOWEVER, THE MECHANISTIC LINK BETWEEN DISEASE PROGRESSION AND GUT DYSBIOSIS HAVE NOT BEEN FULLY ELUCIDATED. IN THIS PROJECT, WE WILL TEST THE HYPOTHESIS THAT THE SYNTHESIS OF NIACIN IN THE GUT IS DYSREGULATED IN ALZHEIMER'S DISEASE, WHICH LEADS TO A REDUCED SUPPLY OF NIACIN TO BRAIN AND EXACERBATES THE DISEASE. CONVERSELY, WE WILL ASSESS IF INCREASING NIACIN SYNTHESIS IN THE GUT AND SUPPLY TO THE BRAIN CAN MITIGATE DISEASE PROGRESSION, WHICH COULD PAVE THE WAY FOR NOVEL THERAPEUTIC STRATEGIES AIMING AT GUT MICROBIOME. NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JAE-EUN MILLER, PHD ENTITLED: A2025016S REPAIRING THE BODY CLOCK TO DELAY ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: BREAKDOWN IN CIRCADIAN RHYTHM IS BOTH A RISK FACTOR AND A SYMPTOM OF ALZHEIMER'S. THIS SUGGESTS A VICIOUS CYCLE OF CIRCADIAN DISRUPTION DRIVING DISEASE, AND DISEASE DRIVING CIRCADIAN DISRUPTION. IF WE COULD PREVENT CIRCADIAN DISRUPTION, WE MAY BE ABLE TO PREVENT DISEASE. THE ROOT CAUSE OF CIRCADIAN DYSFUNCTION IN ALZHEIMER'S IS UNCLEAR. TO ADDRESS THIS, WE WILL DETERMINE HOW TAUOPATHY, A KEY COMPONENT OF ALZHEIMER'S DISEASE, DISRUPTS THE FUNCTION OF THE MASTER CIRCADIAN CLOCK. WE WILL ALSO DEVELOP AN APPROACH RESTORE CIRCADIAN RHYTHM IN A DISEASE MODEL AND DETERMINE IF THIS PREVENTS DISEASE.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: BETH ISRAEL DEACONESS MEDICAL CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FENG TIAN, PHD ENTITLED: A2025017S MONITORING NEURAL ACTIVITY AND NEUROINFLAMMATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: NEUROINFLAMMATION IS ONE KEY HALLMARK OF ALZHEIMER'S DISEASE (AD) AND ONE OF THE MOST ATTRACTIVE DIRECTIONS FOR NOVEL AD DRUG DEVELOPMENT. HOWEVER, IT IS STILL UNCLEAR HOW NEUROINFLAMMATION CONTRIBUTES TO MEMORY LOSS AND COGNITIVE DEFICITS. WE WILL INNOVATIVELY LEVERAGE ADVANCED BRAIN MACHINE INTERFACE AND GENETIC TOOLS TO STUDY THE ROLE BETWEEN NEUROINFLAMMATION AND NEURAL ACTIVITY CHANGES DURING AD PROGRESSION. NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JUSTYNA DOBROWOLSKA ZAKARIA, PHD ENTITLED: A2025019S AMYLOID PRECURSOR PROTEIN PROCESSING THROUGH A NOVEL PATHWAY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALTHOUGH APP, THE PARENT PROTEIN OF ABETA, WAS DISCOVERED 40 YEARS AGO, IT WASN'T UNTIL RECENTLY THAT A NEW CLEAVAGE PRODUCT OF APP WAS DETECTED IN HUMAN BIOFLUIDS. ETA-SECRETASE WAS FOUND TO CUT APP TO GENERATE AETA. AETA HAS BEEN SHOWN TO BE VERY IMPORTANT IN PROCESSES THAT PLAY A ROLE IN MEMORY FORMATION AND ITS LEVELS CHANGE IN MOUSE MODELS WHEN PROSPECTIVE AD THERAPIES ARE ADMINISTERED. NOT MUCH IS KNOWN ABOUT AETA IN HUMANS, AND THUS WE WANT TO DEVELOP A METHOD TO MEASURE HOW QUICKLY AETA IS PRODUCED AND CLEARED IN A HEALTHY OLDER HUMAN AND THEN COMPARE THIS TO AETA METABOLISM IN AD. NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CYRIL POTTIER, PHD ENTITLED: A2025020S EXPLORING THE ORIGIN AND COMPOSITION OF A UNIQUE PATHOLOGY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: SOME PEOPLE WITH EARLY-ONSET ALZHEIMER'S HAVE A RARE TYPE OF PATHOLOGY IN THE BRAIN CALLED "COTTON WOOL PLAQUES" (CWPS), BUT THEIR CAUSE IS STILL A MYSTERY. OUR RESEARCH WILL EXPLORE WHAT MAKES THESE PLAQUES UNIQUE, WHAT PROTEINS THEY CONTAIN COMPARED TO TYPICAL ALZHEIMER'S PLAQUES, AND WHETHER SPECIFIC GENES ARE INVOLVED. BY STUDYING CWPS, WE HOPE TO UNCOVER NEW INSIGHTS INTO HOW ALZHEIMER'S DEVELOPS AND WHY THE DISEASE VARIES BETWEEN PATIENTS. NAME OF ORGANIZATION OR GOVERNMENT: RESEARCH FOUNDATION OF SUNY - UNIVERSITY AT ALBANY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAMIAN ZULOAGA, PHD ENTITLED: A2025021S INTERACTIONS OF PREGNANCY AND MENOPAUSE ON ALZHEIMER'S DISEASE OUTCOMES. INVESTIGATOR'S SUMMARY: WOMEN ARE DISPROPORTIONATELY AFFECTED BY ALZHEIMER'S DISEASE (AD) RELATIVE TO MEN. LIFE COURSE FACTORS UNIQUE TO WOMEN, INCLUDING PREGNANCY AND MENOPAUSE, LIKELY CONTRIBUTE TO FEMALE VULNERABILITY ALTHOUGH HOW THESE TWO FACTORS INTERACT TO AFFECT AD RELATED OUTCOMES IS UNKNOWN. WE PROPOSE TO USE A MOUSE MODEL OF AD TO DETERMINE HOW THE COMBINATION OF PREGNANCY AND MENOPAUSE IMPACT COGNITIVE/BEHAVIORAL FUNCTIONS AND AD ASSOCIATED NEUROPATHOLOGY. NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY REBECCA WALLINGS, DPHIL ENTITLED: A2025023S UNDERSTANDING THE ROLE OF A SUPPRESSED IMMUNE SYSTEM IN FRONTOTEMPORAL DEMENTIA. INVESTIGATOR'S SUMMARY: I PREVIOUSLY PUBLISHED FINDINGS THAT SHOWED IMMUNE CELLS OUTSIDE OF THE BRAIN WHICH CARRY FTD-ASSOCIATED MUTATIONS HAVE A DAMPENED IMMUNE RESPONSE. A DAMPENED IMMUNE RESPONSE IS OFTEN ASSOCIATED WITH IMMUNE CELL EXHAUSTION (ICE); WHEN IMMUNE CELLS LOSE THE ABILITY TO RESPOND TO INFECTIONS AND INFLAMMATION. HERE WE WILL INVESTIGATE 1. THE DOWNSTREAM EFFECTS OF ICE ON OTHER IMMUNE CELLS, AND 2. HOW ICE IN THE PERIPHERY CONTRIBUTES TO DEGENERATION AND INFLAMMATION IN THE BRAIN. THE COMPLETION OF THIS PROPOSAL WILL INFORM US OF THE ROLE OF ICE IN FTD AND IF THIS IS A POTENTIAL THERAPEUTIC TARGET. NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JACK HUMPHREY, PHD ENTITLED: A2025024S TDP-43 IN THE AGING BRAIN: WHEN AND WHERE? INVESTIGATOR'S SUMMARY: DISEASES OF THE AGING BRAIN SUCH AS ALZHEIMER'S ARE CAUSED BY MULTIPLE FACTORS, INCLUDING THE PROTEINS AMYLOID AND TAU, BUT RECENTLY, AN ADDITIONAL PROTEIN TDP-43 HAS BEEN LINKED TO A FASTER DECLINE IN SOME PATIENTS. WE WILL INVESTIGATE TDP-43 IN A SET OF AUTOPSIED BRAINS FROM MULTIPLE DISEASES AND ASSOCIATE ITS PRESENCE TO THE PRESENCE OF AMYLOID AND TAU. WE WILL THEN STUDY WHICH SPECIFIC BRAIN CELLS CONTAIN CHANGES IN TDP-43 LEVELS AND WHAT THAT DOES TO THEM, WHICH COULD HELP TO UNDERSTAND HOW TDP-43 RELATES TO AGING AND DEMENTIA. NAME OF ORGANIZATION OR GOVERNMENT: THE OHIO STATE UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HONGJUN FU, PHD ENTITLED: A2025025S PLCG2 VARIANTS AND THEIR IMPLICATIONS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: PLCG2, AN ENZYME THAT IS IMPORTANT IN CELL-TO-CELL COMMUNICATION, ALSO PLAYS A ROLE IN THE RISK OF DEVELOPING LATE ONSET ALZHEIMER'S DISEASE (AD). THE GENE THAT ENCODES FOR THIS ENZYME HAS AD-ASSOCIATED VARIANTS: ONE OF WHICH PROTECTS AGAINST AD, AND ONE OF WHICH PROMOTES AD. WE AIM TO IDENTIFY THE ROLE THAT THESE TWO AD-ASSOCIATED PLCG2 VARIANTS PLAY IN THE DEVELOPMENT AND PROGRESSION OF MICROTUBULE-ASSOCIATED PROTEIN TAU AGGREGATES, CELL DEATH, AND MEMORY LOSS. NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TODD J. COHEN, PHD ENTITLED: A2025026S HARNESSING THE PROTEIN CHIP/STUB1 TO REDUCE ALZHEIMER'S BRAIN PATHOLOGY. INVESTIGATOR'S SUMMARY: THE RESEARCH FOCUSES ON THE ROLE OF THE PROTEIN CHIP/STUB1 IN ALZHEIMER'S DISEASE, PARTICULARLY ITS ABILITY TO PREVENT THE AGGREGATION OF TAU PROTEINS LINKED TO THE DISEASE'S PROGRESSION. BY ENGINEERING CHIP VARIANTS THAT ENHANCE ITS CHAPERONE FUNCTION, THE STUDY AIMS TO REDUCE TAU PATHOLOGY AND IMPROVE COGNITIVE FUNCTION IN ALZHEIMER'S PATIENTS. THIS INNOVATIVE APPROACH COULD LEAD TO NEW GENE THERAPIES FOR ALZHEIMER'S AND OTHER TAU-RELATED DISEASES. NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, ROCHESTER (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY GAVIN RODDY, MD, PHD ENTITLED: G2025001S DEVELOPING A NEW TREATMENT FOR GLAUCOMA THAT AVOIDS THE USE OF DAILY DROPS. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE LEADING CASE OF IRREVERSIBLE BLINDNESS WORLDWIDE. CURRENT TREATMENTS THAT REQUIRE DAILY INSTILLATION OF EYEDROPS TO LOWER PRESSURE CAUSE SIDE EFFECTS AND FAIL TO ADEQUATELY TREAT MANY PATIENTS. MY LAB DEVELOPED A PRESSURE-LOWERING DRUG THAT ACTS FOR 6 MONTHS WITH A SINGLE INJECTION. WE NOW SEEK TO TEST THIS DRUG IN A LARGE ANIMAL IN HOPES OF BRINGING A NEW THERAPY TO PATIENTS.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KARL JONAS WAHLIN, PHD ENTITLED: G2025002S REPAIRING THE HUMAN RETINA BY CELL REPROGRAMMING. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELL NEURONS CONNECT THE EYE TO THE BRAIN AND WHEN THEY DIE, WHETHER THROUGH GLAUCOMA OR THROUGH ACUTE TRAUMA, THIS LEADS TO PERMANENT VISION LOSS AND BLINDNESS. SIMILAR TO HOW THIS OCCURS THROUGHOUT THE ANIMAL KINGDOM, WE PROPOSE TO DEVELOP THE CAPABILITY TO DO THIS IN HUMAN RETINAL TISSUES THROUGH THE CONVERSION OF EXISTING MLLER CELLS IN THE EYE. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ROB NICKELLS, PHD ENTITLED: G2025003S MITOCHONDRIA IN RETINAL GANGLION CELLS. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELLS RECEIVE INPUT FROM A TREE-LIKE DENDRITIC ARBOR THAT EXHIBITS PATHOLOGY AFTER OPTIC NERVE DAMAGE. THIS STUDY EXAMINES THE BIOLOGY OF ENERGY PRODUCING ORGANELLES CALLED MITOCHONDRIA IN ARBOR PATHOLOGY INCLUDING HOW SPECIALIZED CELLS CALLED MICROGLIA PARTICIPATE IN THIS PROCESS. NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DAN STAMER, PHD ENTITLED: G2025004S ROLE OF A KEY GENE, ANGPTL7 IN STEROID-INDUCED GLAUCOMA. INVESTIGATOR'S SUMMARY: GLUCOCORTICOIDS ARE WIDELY USED ANTI-INFLAMMATORY DRUGS THAT TREAT A VARIETY OF DISEASES, BUT LONG-TERM USE OFTEN RESULTS IN ELEVATED EYE PRESSURE THAT CAN LEAD TO GLAUCOMA. USING THE MOST ADVANCED RESEARCH TECHNOLOGIES, THE PRESENT PROJECT IS DESIGNED TO UNDERSTAND HOW ANGPTL7, A GLAUCOMA RISK GENE, IS INVOLVED IN ELEVATING EYE PRESSURE AFTER GLUCOCORTICOID TREATMENT. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BENJAMIN XU, MD, PHD ENTITLED: G2025005S ENHANCING ACCESS TO GLAUCOMA CARE USING ARTIFICIAL INTELLIGENCE. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE MOST COMMON CAUSE OF IRREVERSIBLE VISION LOSS WORLDWIDE. A PUBLIC HEALTH CRISIS IS EMERGING DUE TO THE RAPID RISE IN GLAUCOMA PREVALENCE, SHORTAGE OF EYECARE PROVIDERS, AND GLARING ACCESS AND EQUITY ISSUES. WE PROPOSE TO INTEGRATE TELEOPHTHALMOLOGY AND ARTIFICIAL INTELLIGENCE (AI) TO ENHANCE THE DELIVERY OF HIGH-QUALITY, REPRODUCIBLE, EQUITABLE, RESOURCE-EFFICIENT GLAUCOMA CARE. NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDATION (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BRAD FORTUNE, OD, PHD ENTITLED: G2025007S ASSESSMENT OF VASCULAR RESISTANCE IN GLAUCOMA. INVESTIGATOR'S SUMMARY: ABNORMAL BLOOD FLOW WITHIN THE EYE IS THOUGHT TO BE ONE FACTOR CONTRIBUTING TO THE DEVELOPMENT AND PROGRESSION OF GLAUCOMA. HOWEVER, QUESTIONS REMAIN ABOUT HOW AND WHEN THIS OCCURS. OUR PROPOSAL AIMS TO DETERMINE WHETHER VASCULAR RESISTANCE IS ELEVATED DURING EARLY STAGES OF GLAUCOMA. OUR RESULTS WILL CONTRIBUTE IMPORTANT KNOWLEDGE AND USEFUL DIAGNOSTIC TOOLS TO THE GLAUCOMA RESEARCH COMMUNITY. NAME OF ORGANIZATION OR GOVERNMENT: THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY TATJANA JAKOBS, MD ENTITLED: G2025008S INTERLEUKIN-10 AS A NEUROPROTECTIVE FACTOR IN GLAUCOMA. INVESTIGATOR'S SUMMARY: VISUAL IMPAIRMENT IN GLAUCOMA IS CAUSED BY THE DEGENERATION AND EVENTUAL DEATH OF RETINAL GANGLION CELLS THROUGH MECHANISMS THAT ARE NOT FULLY UNDERSTOOD. RETINAL MICROGLIA CAN PLAY NEUROPROTECTIVE AND NEUROTOXIC ROLES IN GLAUCOMA. WE IDENTIFIED IL10 AS A CANDIDATE FOR A MICROGLIA-DERIVED FACTOR THAT MAY SELECTIVELY BOOST THE NEUROPROTECTIVE EFFECTS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD ENTITLED: G2025009S ROLE OF IOP ELEVATION IN INCREASING VULNERABILITY OF RETINA TO STRESS. INVESTIGATOR'S SUMMARY: AGING, A PROCESS WHERE DAMAGE ACCUMULATES IN OUR CELLS OVER TIME, MAKES TISSUES MORE SENSITIVE TO ELEVATED INTRAOCULAR PRESSURE (IOP). HOWEVER, IT IS UNKNOWN HOW CELLS BECOME MORE VULNERABLE AS THEY AGE. OUR EXPERIMENTS WILL EXPLORE HOW RETINAS RESPOND TO IOP-RELATED STRESS AND THE MECHANISMS BEHIND THIS VULNERABILITY, AIMING TO FIND NEW WAYS TO PROTECT RETINAL NEURONS FROM GLAUCOMATOUS CHANGES. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY COLLEEN MCDOWELL, PHD ENTITLED: G2025010S NOVEL MECHANISMS REGULATING PRESSURE IN THE EYE. INVESTIGATOR'S SUMMARY: ELEVATED PRESSURE IN THE EYE IS A MAJOR RISK FACTOR FOR GLAUCOMA AND IS DUE TO FLUID BUILDUP AND IMPROPER DRAINAGE IN THE EYE. IT IS KNOWN THAT FLUID DRAINAGE FROM THE EYE IS NOT UNIFORM CIRCUMFERENTIALLY, AND THIS STUDY AIMS TO STUDY HOW THESE SEGMENTAL DIFFERENCES IN FLUID FLOW ARE DEVELOPED AND REGULATED. THESE DATA WILL HELP IDENTIFY NOVEL MECHANISMS TO LOWER PRESSURE IN THE EYE. NAME OF ORGANIZATION OR GOVERNMENT: WILLIAM MARSH RICE UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JERZY SZABLOWSKI, PHD ENTITLED: M2025001N A BLOOD TEST TO MEASURE GENES ASSOCIATED WITH MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: ONE CAN GAIN A LOT OF INFORMATION FROM EXCISING A TISSUE AND ANALYZING ITS BIOCHEMICAL BEHAVIOR, SUCH AS EXPRESSION OF GENES UNDERLYING DISEASE. HOWEVER, FOR THE RETINA SUCH EXCISION IS IMPOSSIBLE AS IT WOULD RESULT IN VISION LOSS. WE ARE USING A CUTTING-EDGE TECHNOLOGY TO MEASURE ACTIVITY OF GENES WITHIN THE RETINA WITH A BLOOD TEST. SPECIFICALLY, WE ARE FOCUSING ON TWO GENES THAT ARE SUSPECTED OF INCREASING THE RISK OF DEVELOPING A VISION DISORDER CALLED AGE-RELATED MACULAR DEGENERATION. IF WE ARE SUCCESSFUL, DOCTORS COULD MEASURE EXPRESSION OF PATIENTS GENES IN RETINA WITHOUT DAMAGING IT.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ANA J CHUCAIR-ELLIOTT, PHD ENTITLED: M2025002N THE ROLE OF AGING, DIET, AND INFLAMMATION IN RPE DEGENERATIVE PROCESSES. INVESTIGATOR'S SUMMARY: AMD IS A BLINDING DISEASE IN WHICH THE CELLS THAT PROCESS VISUAL INFORMATION, PHOTORECEPTORS, DEGENERATE AND DIE. THIS NEURODEGENERATION IS PARTLY DUE TO FAILURE OF THE RETINAL PIGMENTED EPITHELIUM (RPE), THE TISSUE THAT LIES BENEATH THE RETINA, TO SUPPORT NORMAL TISSUE STRUCTURE AND VISUAL FUNCTION. AGING IS THE MAIN RISK FACTOR FOR AMD, BUT DIET AND INFLAMMATION ALSO INCREASE AMD RISK. OUR PROPOSED RESEARCH AIMS TO STUDY HOW AGING AND DIET INTERACT WITH IMMUNE CELLS, MICROGLIA AND MACROPHAGES, TO AFFECT THE RPE GENETIC PROGRAMS AND FUNCTION FOR DISCOVERY OF CANDIDATE TARGETS TO TREAT AMD. NAME OF ORGANIZATION OR GOVERNMENT: NATIONAL EYE INSTITUTE, NIH (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY RUCHI SHARMA, PHD ENTITLED: M2025003N STUDYING THE ROLE OF GENES & THE TONE OF OUR EYE PIGMENT IN AMD. INVESTIGATOR'S SUMMARY: AMD IS A COMMON EYE DISEASE AFFECTING MANY PEOPLE WORLDWIDE. CAUCASIANS ARE MORE LIKELY TO DEVELOP AMD THAN BLACK INDIVIDUALS. WE WILL USE MODELS CREATED FROM PATIENT STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM AND CHOROID TO EXPLORE THE CELLULAR PROCESSES THAT MAKE SOME PEOPLE MORE VULNERABLE TO AMD WHILE OTHERS RESIST IT. OUR GOAL IS TO UNDERSTAND HOW PIGMENTATION, CERTAIN GENETIC FACTORS, AND CELLULAR PROCESSES CONTRIBUTE TO THE RISK OF AMD. THIS RESEARCH WILL HELP US UNCOVER HOW SOME PEOPLE RESIST AMD, WHICH MAY LEAD TO NEW DRUGS TO TREAT OR PREVENT THE DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CHARLES DEBOER, MD, PHD ENTITLED: M2025004N MICROFABRICATED IMPLANT TO TREAT AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THERAPEUTICS TO TREAT AGE-RELATED MACULAR DEGENERATION (AMD) ARE INJECTED INTO THE VITREOUS, WHILE THE ACTUAL SITE OF PATHOLOGY OCCURS DEEPER IN THE EYE, AT THE LEVEL OF THE CHOROID AND RETINA. THE SUPRACHOROIDAL SPACE IS IN DIRECT CONTACT WITH PATHOLOGIC VESSELS IN WET AMD AND DIRECT TARGETING COULD INCREASE LOCAL DRUG CONCENTRATIONS AND POSSIBLY IMPROVE EFFICACY. WE PROPOSE USING A NOVEL DEVICE CONSISTING OF A REFILLABLE DRUG RESERVOIR AND A TINY TUBE INSERTED INTO THE SUPRACHOROIDAL SPACE FOR EXTENDED LOCALIZED DRUG DELIVERY, PROVIDING A NEW WAY TO TREAT AMD. NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MOHAJEET BALVEER BHUCKORY, PHD ENTITLED: M2025007N ELECTRONIC IMPLANTS FOR RESTORING SHARP VISION IN MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: IN ADVANCED AMD, THE LOSS OF THE LIGHT-SENSITIVE CELLS IN THE CENTRAL RETINA, PHOTORECEPTORS (PR), LEAD TO BLINDNESS. HOWEVER, THE REMAINING CONNECTING NEURONS THAT RELAY VISUAL SIGNALS TO THE BRAIN STAY MOSTLY INTACT. OUR CURRENT ELECTRONIC PHOTORECEPTORS (EPR) CAN STIMULATE THESE NEURONS, RESTORING THE FLOW OF VISUAL INFORMATION TO THE BRAIN. THIS PROJECT AIMS TO SIGNIFICANTLY ENHANCE THE RESOLUTION BY DEVELOPING CUTTING-EDGE, CELL-SIZED EPR IMPLANTS, OFFERING THE POTENTIAL TO IMPROVE PROSTHETIC VISION BEYOND LEGAL BLINDNESS AND APPROACH NATURAL VISION. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY VALENCIA FERNANDES, PHD ENTITLED: M2025008F HOW METABOLIC STRESS CAN DRIVE MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS CAUSED BY DAMAGE TO THE RETINAL PIGMENT EPITHELIUM (RPE), WHICH NOURISHES AND SUPPORTS THE RETINA. CHRONIC INFLAMMATION, LIPID ACCUMULATION, AND MITOCHONDRIAL INJURY ACT TOGETHER TO COMPROMISE RPE HEALTH, BUT EXACTLY HOW THIS OCCURS IS NOT WELL UNDERSTOOD. THIS RESEARCH PROPOSES TO IDENTIFY THE KEY PLAYERS IN THIS PROCESS BY FOCUSING ON A PROTEIN CALLED STAT3, WHICH IS A MASTER REGULATOR OF CELL HEALTH, AND INVESTIGATE WHETHER IT CAN BE A DRUG TARGET IN AMD. NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DR. NOBUHIKO SHIRAKI, PHD ENTITLED: M2025011F MICROGLIA'S ROLES IN AMD TO INFORM THERAPIES FOR VISION LOSS PREVENTION. INVESTIGATOR'S SUMMARY: OUTER RETINAL DISEASES, LIKE AMD, CAUSE PERMANENT VISION LOSS DUE TO DAMAGE TO LIGHT-SENSITIVE CELLS. WHILE SOME IMMUNE CELLS HELP CLEAR HARMFUL DEBRIS, RECENT FINDINGS SUGGEST DISTINCT SUBTYPES WITH DIFFERENT FUNCTIONS. GENETIC ANALYSIS IDENTIFIED TWO SUBTYPES IN A CERTAIN IMMUNE CELL, ONE OF WHICH MAY WORSEN INFLAMMATION. STUDIES WITH GENETICALLY MODIFIED MICE SHOWED THAT REDUCING CERTAIN MOLECULES IN THESE CELLS REDUCED RETINAL DAMAGE AFTER LIGHT EXPOSURE. THIS RESEARCH AIMS TO CLARIFY THE IMMUNE CELL ROLES IN AMD, AIMING TO INFORM THERAPIES FOR PREVENTION OF VISION LOSS IN AMD PATIENTS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF IDAHO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ASHLEY FARRE, PHD ENTITLED: M2025012F SHAPING OF NEURONAL CONNECTIONS BY RESIDENT IMMUNE CELLS. INVESTIGATOR'S SUMMARY: IN LATE STAGES OF AGE-RELATED MACULAR DEGENERATION (AMD), LIGHT SENSING CELLS (PHOTORECEPTORS) IN THE EYE DIE, LEADING TO VISION LOSS. TO TREAT THIS WITH FUTURE APPROACHES, WE CAN POTENTIALLY REPLACE PHOTORECEPTORS, BUT IN ORDER TO WORK PROPERLY, THESE CELLS NEED TO BE ABLE TO COMMUNICATE WITH OTHER NEURONS IN THE EYE THAT PROCESS LIGHT INFORMATION AND PASS IT TO THE BRAIN. WITH THIS PROJECT, WE WILL DETERMINE HOW MICROGLIA (IMMUNE CELLS OF THE EYE) COULD HELP NEW PHOTORECEPTORS ESTABLISH CONNECTIONS WITH OTHER NEURONS, POTENTIALLY MAKING FUTURE AMD TREATMENTS MORE EFFECTIVE. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JAESOO JUNG, PHD ENTITLED: M20250013F HEPARAN SULFATE REGULATION OF HTRA1-MEDIATED PROTEOSTASIS IN BRUCH'S MEMBRANE IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: HTRA1 IS A STRONG GENETIC RISK FACTOR FOR AGE-RELATED MACULAR DEGENERATION (AMD), BUT ITS NATURAL SUBSTRATES IN BRUCH'S MEMBRANE (BRM) REMAIN UNKNOWN. TO UNCOVER HOW ALTERED HTRA1 PROTEOLYSIS CONTRIBUTES TO DRUSEN FORMATION, WE WILL USE ISOTOPE-LABELING DEGRADOMICS TO IDENTIFY ITS ENDOGENOUS SUBSTRATES. WE WILL THEN DEVELOP A HIGH-TIME-RESOLVING HOMOGENEOUS TIME-RESOLVED FLUORESCENCE (HTRF) ASSAY TO EVALUATE HOW HEPARAN SULFATES MODULATE HTRA1-MEDIATED HYDROLYSIS OF THESE CANDIDATE SUBSTRATES, PROVIDING INSIGHT INTO MECHANISMS DRIVING EARLY AMD PATHOLOGY.
PART II, LINE 1(H) CONTINUED	NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021010 MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL (HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) 1,877,858 DOWNLOADS IN 2024; 2) JOURNAL CITATION REPORTS (JCR) TRACKED CITATIONS: 9,015 IN 2022; 9,806 IN 2023; AND 11,362 IN 2024; 3) JOURNAL IMPACT FACTOR: 15.1 IN 2022; 15.1 IN 2023; 17.5 IN 2024; 4) 2024 JCR RANKING: MOLECULAR NEURODEGENERATION RANKED NO. 4 AMONG 314 NEUROSCIENCE JOURNALS (WITHIN THE TOP 1.1%). NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021011 INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION" (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. ISMND'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES. NAME OF ORGANIZATION OR GOVERNMENT: MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2025003 THE CONCUSSION ASSESSMENT, RESEARCH, & EDUCATION (CARE) CONSORTIUM BIOBANK. INVESTIGATOR'S SUMMARY: THE OVERARCHING GOAL IS TO LEVERAGE THE DEEPLY ENRICHED CARE COHORT OF MALE AND FEMALE COLLEGIATE ATHLETES AND MILITARY PERSONNEL WITH AND WITHOUT MILD TBI (MTBI)/CONCUSSION AND/OR REPETITIVE HEAD IMPACT EXPOSURE, TO DETERMINE IF A PANEL OF ADRD GENOMIC FACTORS CAN IDENTIFY YOUNG ADULTS (3RD AND 4TH DECADE OF LIFE) WITH VERY EARLY INDICATORS CONSISTENT WITH PRECLINICAL ADRD, WHO MIGHT BENEFIT FROM PRIMARY PREVENTIVE STRATEGIES (ELIMINATION OF HEAD IMPACT EXPOSURE), OR EARLY CONSIDERATION OF RECENTLY APPROVED DISEASE MODIFYING THERAPIES (DMTS).

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
STACY PAGOS HALLER
PRESIDENT/CEO	$423,113	$0	$0	$0	$1,715	$0	$0	$0	$46,677	$0	$471,505	$0	$0	$0
NANCY KEACH
SR. VP, STRATEGIC PARTNERSHIPS	$268,573	$0	$0	$0	$1,584	$0	$0	$0	$51,713	$0	$321,870	$0	$0	$0
R BRIAN ELDERTON
SR. VP, DEVELOPMENT	$259,608	$0	$0	$0	$1,715	$0	$0	$0	$40,046	$0	$301,369	$0	$0	$0
JONATHAN WALSH
SVP, FINANCE & ADMINISTRATION	$226,326	$0	$0	$0	$460	$0	$0	$0	$4,251	$0	$231,037	$0	$0	$0
DIANE BOVENKAMP PHD
VP, SCIENTIFIC AFFAIRS	$195,690	$0	$0	$0	$552	$0	$0	$0	$24,358	$0	$220,600	$0	$0	$0
SHARYN ROSSI - PHD DIR OF
SCIENT. PROGRAMS, NEUROSCIENCE	$125,492	$0	$0	$0	$240	$0	$0	$0	$42,143	$0	$167,875	$0	$0	$0
LISA MORGAN
SENIOR DIRECTOR, ANNUAL GIVING	$134,563	$0	$0	$0	$552	$0	$0	$0	$22,867	$0	$157,982	$0	$0	$0
PREETI SUBRAMANIAN - PHD DIR
OF SCIENT. PROGRAMS, VISION SCIENCE	$139,571	$0	$0	$0	$360	$0	$0	$0	$16,400	$0	$156,331	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 3	FormAndLineReferenceDesc
Explanation	THE LAST COMPENSATION SURVEY WAS COMPLETED ON 3/9/2022.	ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	45	ContributionCnt
Noncash Contributions Rpt F990	$394,954	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (1)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	Yes (1)	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, COLUMN (B):	BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN B.
PART I, LINE 32B:	BRIGHTFOCUS ENGAGED THE SERVICES OF A COMMERCIAL REAL ESTATE BROKER TO SOLICIT AND SELL THE COMMERCIAL REAL ESTATE DONATED TO THE ORGANIZATION 25 YEARS AGO.

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:	BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, MORE THAN 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE DISEASES. BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN $310 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS IN 28 COUNTRIES THROUGH ITS THREE PROGRAMS: ALZHEIMER'S DISEASE RESEARCH, MACULAR DEGENERATION RESEARCH, AND NATIONAL GLAUCOMA RESEARCH. THE RESEARCH WE SUPPORT IS CAREFULLY CHOSEN BY OUR SCIENTIFIC REVIEW COMMITTEES, COMPRISING WORLD-RENOWNED RESEARCHERS AND LEADERS IN THEIR FIELDS. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO UNDERSTANDING, DIAGNOSING, PREVENTING, AND TREATING THESE DISEASES AND PROVIDES SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS FUNDED GRANTEES WERE ABLE TO OBTAIN 8 TIMES THE ORIGINAL FUNDING AMOUNT PROVIDED BY BRIGHTFOCUS, TO CONTINUE TO DEVELOP THEIR INNOVATIONS. THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM OTHER SOURCES THAT ARE UP TO 8 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS. ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE, EXPERT-VETTED EDUCATIONAL MATERIALS TO HUNDREDS OF THOUSANDS OF PEOPLE IMPACTED BY THESE DISEASES NATIONWIDE. WE GROUND THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS AND BREAKTHROUGHS. BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS. BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S, MAKE A PLAN TODAY: GET YOUR EYES CHECKED, AND FINDING ANSWERS IN THE FIGHT AGAINST ALZHEIMER'S SEEK TO RAISE AWARENESS ABOUT THESE DISEASES AND THE IMPORTANCE OF EARLY DETECTION. SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2025, THESE PSA MESSAGES GENERATED $9,240,763 IN DONATED MEDIA SERVICES AND GARNERED OVER 425 MILLION IMPRESSIONS. WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY PRODUCE NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES. PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES. SPECIFICALLY, BRIGHTFOCUS PRODUCES AND DISSEMINATES FREE PROGRAMS INCLUDING: BRIGHTFOCUS VISION CHATS. SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES. ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING WORLD-RENOWNED RESEARCH SCIENTISTS WHO SHARE THE LATEST BREAKTHROUGHS AND FINDINGS IN THE FIELD. ALL EPISODES ARE RECORDED AND AVAILABLE TO WATCH ON DEMAND ON OUR WEBSITE AND YOUTUBE. WE REGULARLY PUBLISH ARTICLES AND RESOURCES PROVIDING LAY-PERSON INFORMATION ABOUT COMMONLY ASKED DISEASE QUESTIONS. TWO MILLION VISITORS EACH YEAR TO OUR WEBSITE, WWW.BRIGHTFOCUS.ORG, FIND A WEALTH OF INFORMATION ON RESEARCH, SYMPTOMS, TREATMENTS, AND CAREGIVER SUPPORT. BRIGHTFOCUS IS A PRESENTING PARTNER OF SEVERAL DOCUMENTARY FILMS, INCLUDING TAKING CARE, REMEMBERING GENE WILDER, AND GLEN CAMPBELL: I'LL BE ME, AND EXECUTES ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS ARE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH. BRIGHTFOCUS HAS A LONG-RUNNING AND ROBUST DIRECT MAIL PROGRAM ACROSS THE THREE RESEARCH AREAS IT SUPPORTS. BRIGHTFOCUS MAILS AWARENESS-RAISING MATERIALS ACROSS ITS THREE PROGRAM AREAS TO OVER 600,000 NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON: RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK. LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE. RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE. BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES. BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	ALZHEIMER'S DISEASE RESEARCH (ADR) ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND BLACK AND HISPANIC ADULTS MOST AT RISK. ALZHEIMER'S DISEASE RESEARCH (ADR), A BRIGHTFOCUS FOUNDATION PROGRAM, FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, EARLY DETECTION, TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE. SINCE INCEPTION, ADR HAS INVESTED NEARLY $190 MILLION IN RESEARCH GRANTS TO DEFEAT ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDING MARCH 31, 2025, ADR AWARDED $10,207,897 IN PEER-REVIEWED GRANT AWARDS TO 40 NEW RESEARCH PROJECTS. NOTABLE PROJECTS INCLUDE: INFLAMMATORY FACTORS DRIVING MYELIN DYSFUNCTION, NOVEL INTERVENTIONS USING FOCUSED ULTRASOUND TECHNOLOGY, HARNESSING DISEASE DIFFERENCES TO GENERATE PERSONALIZED PROTEIN SIGNATURES, THE ROLE OF MULTIPLE PREGNANCIES AND MENOPAUSE ON DEMENTIA RISK, AND DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I. BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS. DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL IN OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE. BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL MOLECULAR NEURODEGENERATION AS THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN OPEN-ACCESS JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/ADR.
FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:	MACULAR DEGENERATION RESEARCH (MDR) AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES. MACULAR DEGENERATION RESEARCH (MDR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY $57 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS, UNDERSTANDING THE CAUSES AND DISEASE PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF METABOLISM AND IMMUNE RESPONSE IN DISEASE RISK, GENES, AND NEW IMAGING, MACHINE LEARNING, AND SCREENING TECHNIQUES. MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2025, MDR AWARDED $3,774,565 IN PEER-REVIEWED GRANT AWARDS TO 12 NEW RESEARCH PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/MDR.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	NATIONAL GLAUCOMA RESEARCH (NGR) GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN FOUR MILLION AMERICANS ARE LIVING WITH GLAUCOMA. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE. NATIONAL GLAUCOMA RESEARCH (NGR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY $53 MILLION WORLDWIDE IN RESEARCH GRANTS TOWARD THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND GLAUCOMA RISK, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS. NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2025, NGR AWARDED $1,818,979 IN PEER-REVIEWED GRANT AWARDS FOR 10 NEW PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/NGR.
FORM 990, PART VI, SECTION B, LINE 11B	A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.
FORM 990, PART VI, SECTION B, LINE 12C	BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY. EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.
FORM 990, PART VI, SECTION B, LINE 15	BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR. BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE CONSIDERING THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD, INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED YEARLY BY THE BOARD OF DIRECTORS USING AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, THAT INCLUDES A SELF-ASSESSMENT AND A BOARD OF DIRECTOR'S ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES, AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN SIMILAR CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS CONSIDERS TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING. THE BOARD OF DIRECTORS SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE CONSIDERING THE EVALUATION AND COMPARABILITY DATA. THE PRESIDENT/CEO IS CHARGED WITH SETTING THE SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.
FORM 990, PART VI, SECTION C, LINE 19	BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON ITS WEBSITE AT WWW.BRIGHTFOCUS.ORG.
FORM 990, PART XI, LINE 9:	RECOVERIES OF PRIOR YEAR GRANTS 105,727. CHANGE IN PRESENT VALUE OF GRANTS 4,590.
FORM 990, PART XII, LINE 2C:	THE PROCESS HAS NOT CHANGED FROM PRIOR YEAR.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Total IncomeTotalIncomeAmt	End Of Year AssetsEndOfYearAssetsAmt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt
NATIONAL DEVELOPMENT LLC
22512 GATEWAY CENTER DRIVE	CLARKSBURG	MD	20871	237337229	PROPERTY RENTAL AND MANAGEMENT	MD	$8,684,432	$24,681	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE LLC
22512 GATEWAY CENTER DRIVE	CLARKSBURG	MD	20871	237337229	OWNER OF BRIGHTFOCUS HEADQUARTERS	MD	$0	$2,981,266	BRIGHTFOCUS FOUNDATION